CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | amino acid amide |
|
Accession: | CHEBI:22475
|
browse the term
|
Definition: | An amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group. |
|
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of CCL2 mRNA] |
CTD |
PMID:31586451 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of CTSK mRNA] |
CTD |
PMID:31586451 |
|
NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
|
|
G |
Ctss |
cathepsin S |
multiple interactions |
ISO |
anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of CTSS mRNA] |
CTD |
PMID:31586451 |
|
NCBI chr 2:197,655,780...197,679,768
Ensembl chr 2:197,655,786...197,679,458
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of CYBA mRNA] |
CTD |
PMID:31586451 |
|
NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of CYBB mRNA] |
CTD |
PMID:31586451 |
|
NCBI chr X:14,578,330...14,610,049
Ensembl chr X:14,578,264...14,612,547
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
decreases activity |
ISO |
anagliptin results in decreased activity of DPP4 protein |
CTD |
PMID:31586451 |
|
NCBI chr 3:48,291,055...48,372,672
Ensembl chr 3:48,291,055...48,372,672
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of ICAM1 mRNA] |
CTD |
PMID:31586451 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of MMP2 mRNA] |
CTD |
PMID:31586451 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of MMP9 mRNA] |
CTD |
PMID:31586451 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anagliptin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein]]; anagliptin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 mRNA]; anagliptin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein] |
CTD |
PMID:31586451 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of VCAM1 mRNA] |
CTD |
PMID:31586451 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
|
G |
Abca2 |
ATP binding cassette subfamily A member 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ABCA2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:2,648,787...2,668,770
Ensembl chr 3:2,648,885...2,668,809
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases expression decreases activity |
ISO |
ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein] [Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]] Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA Bortezomib results in decreased activity of ABCB1 protein |
CTD |
PMID:25576094 PMID:30482226 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ABCC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
Bortezomib results in increased expression of ABCC2 mRNA |
CTD |
PMID:21215737 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ABCC4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Abhd16a |
abhydrolase domain containing 16A, phospholipase |
increases expression |
ISO |
Bortezomib results in increased expression of ABHD16A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:5,080,070...5,094,935
Ensembl chr20:5,080,070...5,094,935
|
|
G |
Abhd2 |
abhydrolase domain containing 2, acylglycerol lipase |
increases expression |
ISO |
Bortezomib results in increased expression of ABHD2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:140,998,240...141,087,405
Ensembl chr 1:140,998,240...141,087,405
|
|
G |
Abi1 |
abl-interactor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of ABI1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:89,951,662...90,033,334
Ensembl chr17:89,951,752...90,033,328
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein] |
CTD |
PMID:15039284 PMID:17495969 PMID:21195056 |
|
NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO |
[Butyrates co-treated with Bortezomib] results in increased activity of ACE protein mutant form |
CTD |
PMID:20454656 |
|
NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
|
|
G |
Acot7 |
acyl-CoA thioesterase 7 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ACOT7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:169,357,582...169,450,215
Ensembl chr 5:169,357,517...169,450,219
|
|
G |
Adam10 |
ADAM metallopeptidase domain 10 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ADAM10 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:77,107,355...77,237,483
Ensembl chr 8:77,107,536...77,237,483
|
|
G |
Adm |
adrenomedullin |
multiple interactions decreases expression |
ISO |
Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of ADM mRNA] Bortezomib results in decreased expression of ADM mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
|
|
G |
Aff1 |
AF4/FMR2 family, member 1 |
increases expression |
ISO |
Bortezomib results in increased expression of AFF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:7,222,883...7,384,916
Ensembl chr14:7,226,586...7,384,876
|
|
G |
Aff4 |
AF4/FMR2 family, member 4 |
increases expression |
ISO |
Bortezomib results in increased expression of AFF4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:38,692,167...38,773,021
Ensembl chr10:38,692,211...38,773,021
|
|
G |
Agk |
acylglycerol kinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of AGK mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:68,483,345...68,561,518
Ensembl chr 4:68,483,320...68,560,801
|
|
G |
Agrn |
agrin |
decreases expression |
ISO |
Bortezomib results in decreased expression of AGRN mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:173,589,910...173,622,813
Ensembl chr 5:173,589,819...173,622,645
|
|
G |
Agtpbp1 |
ATP/GTP binding protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of AGTPBP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:5,510,009...5,614,416
Ensembl chr17:5,511,385...5,614,435
|
|
G |
Agtrap |
angiotensin II receptor-associated protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of AGTRAP mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:164,888,069...164,898,387
Ensembl chr 5:164,886,813...164,898,420
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
affects localization multiple interactions |
ISO |
Bortezomib affects the localization of AIFM1 protein [Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein |
CTD |
PMID:12893773 PMID:16024631 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Aifm2 |
apoptosis inducing factor, mitochondria associated 2 |
increases expression |
ISO |
Bortezomib results in increased expression of AIFM2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:31,329,047...31,353,548
Ensembl chr20:31,339,787...31,352,906
|
|
G |
Aim2 |
absent in melanoma 2 |
increases expression |
ISO |
Bortezomib results in increased expression of AIM2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:91,919,834...91,963,080
Ensembl chr13:91,954,138...91,962,588
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
increases expression |
ISO |
Bortezomib results in increased expression of AKR1B1 mRNA; Bortezomib results in increased expression of AKR1B1 protein |
CTD |
PMID:21215737 |
|
NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression |
ISO |
Bortezomib results in increased expression of AKR1B10 mRNA; Bortezomib results in increased expression of AKR1B10 protein |
CTD |
PMID:21215737 |
|
NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
|
|
G |
Akr1b8 |
aldo-keto reductase family 1, member B8 |
increases expression |
EXP |
Bortezomib results in increased expression of AKR1B8 mRNA |
CTD |
PMID:20830808 |
|
NCBI chr 4:61,772,064...61,784,637
Ensembl chr 4:61,771,970...61,828,657
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
affects expression |
ISO |
Bortezomib affects the expression of AKR1C2 mRNA |
CTD |
PMID:21215737 |
|
NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases expression |
ISO |
Bortezomib results in increased expression of AKR1C3 mRNA |
CTD |
PMID:21215737 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 5:157,759,448...157,768,473
Ensembl chr 5:157,759,416...157,768,471
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression decreases activity |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form] Bortezomib results in decreased activity of AKT1 protein |
CTD |
PMID:15039284 PMID:15781649 PMID:16118318 PMID:16985072 PMID:18445700 PMID:18701494 PMID:19261616 PMID:19457607 PMID:20701607 PMID:21472287 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ALDH18A1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:259,641,673...259,674,521
Ensembl chr 1:259,641,676...259,674,425 Ensembl chr 1:259,641,676...259,674,425
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ALDH5A1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:42,133,076...42,159,413
Ensembl chr17:42,133,076...42,159,413
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase 6 family, member A1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ALDH6A1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:108,146,552...108,167,185
Ensembl chr 6:108,146,582...108,167,185
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
increases response to substance |
ISO |
ALOX12 gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr10:56,851,734...56,864,049
Ensembl chr10:56,851,734...56,864,005
|
|
G |
Anapc11 |
anaphase promoting complex subunit 11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ANAPC11 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr10:109,774,779...109,785,877
Ensembl chr10:109,774,878...109,785,877
|
|
G |
Anapc5 |
anaphase-promoting complex subunit 5 |
decreases expression increases expression |
ISO |
Bortezomib results in decreased expression of ANAPC5 mRNA Bortezomib results in increased expression of ANAPC5 mRNA |
CTD |
PMID:17895889 PMID:20977926 |
|
NCBI chr12:39,209,134...39,242,696
Ensembl chr12:39,209,129...39,242,690
|
|
G |
Ankrd9 |
ankyrin repeat domain 9 |
increases expression |
ISO |
Bortezomib results in increased expression of ANKRD9 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:135,409,698...135,412,552
Ensembl chr 6:135,410,030...135,412,312
|
|
G |
Ano10 |
anoctamin 10 |
increases expression |
ISO |
Bortezomib results in increased expression of ANO10 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:130,812,941...130,931,021
Ensembl chr 8:130,813,214...130,930,990
|
|
G |
Ap1s1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of AP1S1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:22,665,128...22,676,079
Ensembl chr12:22,665,112...22,676,075
|
|
G |
Ap2a1 |
adaptor related protein complex 2 subunit alpha 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of AP2A1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:100,896,582...100,926,443
Ensembl chr 1:100,896,947...100,926,335
|
|
G |
Apobr |
apolipoprotein B receptor |
decreases expression |
ISO |
Bortezomib results in decreased expression of APOBR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:197,999,209...198,003,839
Ensembl chr 1:197,999,037...198,003,839
|
|
G |
Apool |
apolipoprotein O-like |
increases expression |
ISO |
Bortezomib results in increased expression of APOOL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:83,678,269...83,750,550
Ensembl chr X:83,678,339...83,750,549
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
increases expression |
ISO |
Bortezomib results in increased expression of AQP3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:25752796 PMID:30818834 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Arf6 |
ADP-ribosylation factor 6 |
increases expression |
ISO |
Bortezomib results in increased expression of ARF6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:91,697,109...91,698,257
Ensembl chr 6:91,697,109...91,698,255
|
|
G |
Arfgap1 |
ADP-ribosylation factor GTPase activating protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARFGAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:176,475,847...176,490,642
Ensembl chr 3:176,475,893...176,489,925
|
|
G |
Arhgap1 |
Rho GTPase activating protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARHGAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:80,555,196...80,576,881
Ensembl chr 3:80,555,196...80,576,856
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARHGDIA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:109,754,012...109,757,506
Ensembl chr10:109,754,004...109,757,550
|
|
G |
Arid3b |
AT-rich interaction domain 3B |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 8:62,569,601...62,616,837
Ensembl chr 8:62,569,528...62,616,828
|
|
G |
Arl4c |
ADP ribosylation factor like GTPase 4C |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARL4C mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:95,783,651...95,787,092
Ensembl chr 9:95,786,508...95,787,094
|
|
G |
Arl8a |
ADP-ribosylation factor like GTPase 8A |
increases expression |
ISO |
Bortezomib results in increased expression of ARL8A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:51,972,974...51,981,976
Ensembl chr13:51,972,974...51,981,976
|
|
G |
Arrb1 |
arrestin, beta 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARRB1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
|
|
G |
Asap1 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ASAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:104,670,076...104,951,090
Ensembl chr 7:104,669,672...104,801,045
|
|
G |
Ate1 |
arginyltransferase 1 |
increases expression |
ISO |
Bortezomib results in increased expression of ATE1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:200,810,741...200,885,593 NCBI chr 1:200,958,564...201,082,100
Ensembl chr 1:200,810,771...201,082,727
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions increases phosphorylation increases expression |
ISO |
pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein] Bortezomib results in increased expression of ATF2 mRNA |
CTD |
PMID:12393500 PMID:20977926 |
|
NCBI chr 3:60,721,137...60,795,951
Ensembl chr 3:60,721,135...60,795,951
|
|
G |
Atf3 |
activating transcription factor 3 |
increases response to substance increases expression multiple interactions |
ISO EXP |
ATF3 results in increased susceptibility to Bortezomib Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA] |
CTD |
PMID:17898295 PMID:20022965 PMID:20830808 PMID:21762082 PMID:25522274 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression decreases response to substance |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA] Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein ATF4 results in decreased susceptibility to Bortezomib |
CTD |
PMID:15509775 PMID:16928686 PMID:20022965 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atf5 |
activating transcription factor 5 |
increases expression |
ISO |
Bortezomib results in increased expression of ATF5 mRNA |
CTD |
PMID:17898295 |
|
NCBI chr 1:100,807,821...100,812,410
Ensembl chr 1:100,808,241...100,810,522
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]] |
CTD |
PMID:22842577 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases cleavage |
ISO |
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein] |
CTD |
PMID:12393500 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:81,852,423...81,881,565
Ensembl chr 1:81,852,429...81,881,549
|
|
G |
Atp2a1 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 |
multiple interactions affects response to substance |
ISO |
ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1] ATP2A1 protein affects the susceptibility to Bortezomib |
CTD |
PMID:25576094 |
|
NCBI chr 1:197,855,912...197,875,038
|
|
G |
Atp6v0e1 |
ATPase H+ transporting V0 subunit e1 |
increases expression |
ISO |
Bortezomib results in increased expression of ATP6V0E1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:16,769,857...16,792,930
Ensembl chr10:16,769,666...16,792,909
|
|
G |
B2m |
beta-2 microglobulin |
decreases expression |
ISO |
Bortezomib results in decreased expression of B2M protein |
CTD |
PMID:17204182 |
|
NCBI chr 3:114,087,287...114,093,311
Ensembl chr 3:114,087,287...114,093,309
|
|
G |
B3gnt2 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of B3GNT2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:107,592,336...107,617,189
Ensembl chr14:107,592,336...107,617,161
|
|
G |
B4galt6 |
beta-1,4-galactosyltransferase 6 |
increases expression |
ISO |
Bortezomib results in increased expression of B4GALT6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:15,462,913...15,525,584
Ensembl chr18:15,462,913...15,525,579
|
|
G |
Bag3 |
BAG cochaperone 3 |
increases expression |
ISO |
Bortezomib results in increased expression of BAG3 mRNA |
CTD |
PMID:15509775 PMID:17659339 PMID:20471514 |
|
NCBI chr 1:199,941,258...199,965,191
Ensembl chr 1:199,941,161...199,965,191
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions increases expression |
ISO |
[nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein] Bortezomib results in increased expression of BAK1 protein |
CTD |
PMID:12902978 PMID:17326159 PMID:20850924 |
|
NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
increases response to substance |
ISO |
BARD1 mutant form results in increased susceptibility to Bortezomib |
CTD |
PMID:25522274 |
|
NCBI chr 9:78,297,723...78,368,777
Ensembl chr 9:78,294,834...78,369,031
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
[Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]] Bortezomib results in increased expression of BAX protein |
CTD |
PMID:12902978 PMID:18445700 PMID:18718063 PMID:20383943 PMID:20850924 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
Bortezomib results in increased expression of BBC3 mRNA; Bortezomib results in increased expression of BBC3 protein |
CTD |
PMID:17898295 PMID:20051518 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression increases cleavage decreases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form] Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein |
CTD |
PMID:15173093 PMID:15781649 PMID:16022909 PMID:16118318 PMID:16446371 PMID:17156654 PMID:17326159 PMID:17327374 PMID:17351739 PMID:17895889 PMID:18718063 PMID:18928586 PMID:20051518 PMID:20383943 PMID:20471514 PMID:21302442 PMID:24377552 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions increases expression |
ISO |
[romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein Bortezomib results in increased expression of BCL2A1A protein |
CTD |
PMID:18223231 PMID:20051518 |
|
NCBI chr 8:96,551,424...96,559,527
Ensembl chr 8:96,551,245...96,559,483
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression increases expression increases cleavage decreases response to substance |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein] Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein Bortezomib results in increased expression of BCL2L1 protein BCL2L1 protein results in decreased susceptibility to Bortezomib |
CTD |
PMID:15039284 PMID:15543232 PMID:15781649 PMID:16118318 PMID:16446371 PMID:16617327 PMID:16904634 PMID:17326159 PMID:17327374 PMID:17351739 PMID:18223231 PMID:19100720 PMID:20051518 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions increases expression increases activity increases response to substance |
ISO |
[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein] Bortezomib results in increased expression of BCL2L11 protein Bortezomib results in increased activity of BCL2L11 protein BCL2L11 results in increased susceptibility to Bortezomib |
CTD |
PMID:15173094 PMID:16024631 PMID:16446371 PMID:17326159 PMID:18566236 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
increases expression |
ISO |
Bortezomib results in increased expression of BCL2L2 mRNA |
CTD |
PMID:18928586 |
|
NCBI chr15:33,543,774...33,549,165
Ensembl chr15:33,544,312...33,549,164
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
multiple interactions decreases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL3 mRNA Bortezomib results in decreased expression of BCL3 mRNA |
CTD |
PMID:20471514 PMID:20977926 |
|
NCBI chr 1:80,730,758...80,745,273
Ensembl chr 1:80,730,499...80,744,831
|
|
G |
Bcl6 |
BCL6, transcription repressor |
increases expression |
ISO |
Bortezomib results in increased expression of BCL6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:80,255,790...80,279,075
Ensembl chr11:80,255,790...80,279,075
|
|
G |
Bcl7a |
BAF chromatin remodeling complex subunit BCL7A |
decreases expression |
ISO |
Bortezomib results in decreased expression of BCL7A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:38,659,294...38,691,191
Ensembl chr12:38,662,303...38,691,075
|
|
G |
Bcr |
BCR activator of RhoGEF and GTPase |
decreases expression |
ISO |
Bortezomib results in decreased expression of BCR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:14,421,250...14,546,406
Ensembl chr20:14,421,141...14,545,772
|
|
G |
Becn1 |
beclin 1 |
multiple interactions decreases response to substance |
ISO |
BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein] BECN1 protein results in decreased susceptibility to Bortezomib |
CTD |
PMID:22842577 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases cleavage multiple interactions |
ISO |
Bortezomib results in increased cleavage of BID protein [Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein] |
CTD |
PMID:12893773 PMID:12902978 PMID:15930312 PMID:17326159 PMID:17351739 PMID:17898295 PMID:19261616 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Bik |
BCL2-interacting killer |
increases response to substance increases expression increases activity |
ISO |
BIK results in increased susceptibility to Bortezomib Bortezomib results in increased expression of BIK protein Bortezomib results in increased activity of BIK protein |
CTD |
PMID:16446371 PMID:18566236 |
|
NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
|
|
G |
Bin1 |
bridging integrator 1 |
increases expression |
ISO |
Bortezomib results in increased expression of BIN1 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr18:25,163,575...25,222,139
Ensembl chr18:25,163,561...25,222,135
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of BIRC2 protein [geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein |
CTD |
PMID:15543232 PMID:15781649 PMID:17626072 PMID:18223231 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression increases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of BIRC3 protein Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA |
CTD |
PMID:17626072 PMID:24085292 PMID:25522274 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression multiple interactions increases expression |
ISO |
Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein [irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein Bortezomib results in increased expression of BIRC5 protein |
CTD |
PMID:16373703 PMID:17510429 PMID:17898295 PMID:18223231 PMID:18850583 PMID:19636294 PMID:20977926 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Birc7 |
baculoviral IAP repeat-containing 7 |
multiple interactions decreases expression |
ISO |
arsenic trioxide promotes the reaction [Bortezomib results in decreased expression of BIRC7 mRNA] |
CTD |
PMID:21867610 |
|
NCBI chr 3:176,438,335...176,443,864
Ensembl chr 3:176,439,199...176,443,195
|
|
G |
Bles03 |
basophilic leukemia expressed protein BLES03 |
decreases expression |
ISO |
Bortezomib results in decreased expression of C11ORF68 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:220,806,563...220,808,817
Ensembl chr 1:220,806,473...220,808,804
|
|
G |
Blk |
BLK proto-oncogene, Src family tyrosine kinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of BLK mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:46,555,552...46,593,778
Ensembl chr15:46,555,188...46,593,653
|
|
G |
Blvrb |
biliverdin reductase B |
increases expression |
ISO |
Bortezomib results in increased expression of BLVRB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:84,256,063...84,273,726
Ensembl chr 1:84,256,159...84,274,075
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
Bortezomib results in increased expression of BNIP3 protein |
CTD |
PMID:20110775 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
decreases expression multiple interactions increases response to substance decreases ubiquitination |
ISO |
Bortezomib results in decreased expression of BRCA1 mRNA BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib] [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein] Bortezomib results in decreased ubiquitination of BRCA1 protein |
CTD |
PMID:21917757 PMID:25522274 |
|
NCBI chr10:89,394,821...89,455,093
Ensembl chr10:89,394,803...89,454,681
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of BRCA2 mRNA [arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA |
CTD |
PMID:21917757 PMID:25913414 |
|
NCBI chr12:503,660...544,754
Ensembl chr12:504,007...544,748
|
|
G |
Brcc3 |
BRCA1/BRCA2-containing complex, subunit 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of BRCC3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:9,863,380...9,865,920
Ensembl chr 9:9,863,404...9,865,920
|
|
G |
Brf2 |
BRF2, RNA polymerase III transcription initiation factor subunit |
increases expression |
ISO |
Bortezomib results in increased expression of BRF2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:69,089,955...69,094,678
Ensembl chr16:69,089,955...69,094,680
|
|
G |
Bsdc1 |
BSD domain containing 1 |
increases expression |
ISO |
Bortezomib results in increased expression of BSDC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:147,661,618...147,689,766
Ensembl chr 5:147,661,618...147,689,759
|
|
G |
Ca9 |
carbonic anhydrase 9 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CA9 protein |
CTD |
PMID:16061869 |
|
NCBI chr 5:59,008,277...59,015,535
Ensembl chr 5:59,008,933...59,015,528
|
|
G |
Caap1 |
caspase activity and apoptosis inhibitor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CAAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:113,479,416...113,532,961
Ensembl chr 5:113,480,547...113,532,878
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
decreases degradation |
ISO |
Bortezomib results in decreased degradation of CACNA1H protein |
CTD |
PMID:30552955 |
|
NCBI chr10:14,730,932...14,789,201
Ensembl chr10:14,730,941...14,788,617
|
|
G |
Calr |
calreticulin |
multiple interactions increases expression |
ISO |
[CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein] [Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]] |
CTD |
PMID:30482226 |
|
NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
|
|
G |
Capn15 |
calpain 15 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CAPN15 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:15,319,772...15,346,607
Ensembl chr10:15,319,774...15,346,374
|
|
G |
Card9 |
caspase recruitment domain family, member 9 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in increased expression of CARD9 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 3:3,798,346...3,806,841
Ensembl chr 3:3,798,347...3,806,713
|
|
G |
Casp12 |
caspase 12 |
increases cleavage |
ISO |
Bortezomib results in increased cleavage of CASP12 protein |
CTD |
PMID:15509775 PMID:16357177 |
|
NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
|
|
G |
Casp2 |
caspase 2 |
multiple interactions increases response to substance increases cleavage |
ISO |
benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein] CASP2 results in increased susceptibility to Bortezomib Bortezomib results in increased cleavage of CASP2 protein |
CTD |
PMID:15509775 PMID:16446371 PMID:18723477 |
|
NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage multiple interactions increases expression |
ISO |
Bortezomib results in increased activity of CASP3 protein Bortezomib results in increased cleavage of CASP3 protein 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [SCIO-469 co-treated with Bortezomib] results in increased activity of CASP3 protein; ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein] 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased activity of CASP3 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP3 protein; [Bortezomib co-treated with abexinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP3 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [Cisplatin co-treated with Bortezomib] results in increased activity of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased activity of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [gallium nitrate results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [NSC606985 results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Thapsigargin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Tunicamycin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein] Bortezomib results in increased expression of CASP3 protein |
CTD |
PMID:12393500 PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 PMID:15514602 PMID:15930312 PMID:16024631 PMID:16118318 PMID:16357177 PMID:16617327 PMID:16675587 PMID:16778179 PMID:16904634 PMID:16985072 PMID:17121930 PMID:17156654 PMID:17326159 PMID:17351739 PMID:17495969 PMID:17510429 PMID:17898295 PMID:17898787 PMID:18005386 PMID:18223231 PMID:18223318 PMID:18342500 PMID:18534018 PMID:18641367 PMID:18718063 PMID:18790767 PMID:19100720 PMID:19261616 PMID:19417023 PMID:19662097 PMID:20022965 PMID:20051518 PMID:20150630 PMID:20383943 PMID:20471514 PMID:20524303 PMID:20850924 PMID:21195056 PMID:21345073 PMID:21472287 PMID:21518486 PMID:22842577 PMID:23063726 PMID:23300809 PMID:24291039 PMID:24377552 PMID:29384525 PMID:30482226 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp4 |
caspase 4 |
multiple interactions increases response to substance increases cleavage increases activity |
ISO |
[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein; CASP4 protein results in increased susceptibility to [Cisplatin co-treated with Bortezomib]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein] CASP4 protein results in increased susceptibility to Bortezomib Bortezomib results in increased activity of CASP4 protein |
CTD |
PMID:16357177 PMID:18641367 |
|
NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
|
|
G |
Casp6 |
caspase 6 |
multiple interactions increases cleavage |
ISO |
Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP6 protein] |
CTD |
PMID:16617327 PMID:17510429 |
|
NCBI chr 2:235,341,326...235,353,715
Ensembl chr 2:235,341,365...235,353,967 Ensembl chr 2:235,341,365...235,353,967
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases cleavage increases activity |
ISO |
[Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein; Bortezomib results in increased cleavage of and results in increased activity of CASP7 protein; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP7 protein] Bortezomib results in increased activity of CASP7 protein |
CTD |
PMID:16024631 PMID:16617327 PMID:16904634 PMID:18342500 PMID:18534018 PMID:20022965 PMID:20524303 PMID:23300809 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases cleavage |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of CASP8 mRNA; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP8 protein; [Bortezomib co-treated with arsenic trioxide] results in increased expression of CASP8 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with vorinostat] results in increased activity of CASP8 protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [IFNA2 protein co-treated with Bortezomib] results in increased activity of CASP8 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of CASP8 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [vorinostat results in increased activity of CASP8 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP8 protein; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP8 protein] |
CTD |
PMID:12393500 PMID:12893773 PMID:12902978 PMID:15070698 PMID:15173093 PMID:15930312 PMID:16024631 PMID:16118318 PMID:16617327 PMID:16778179 PMID:16904634 PMID:17172406 PMID:17326159 PMID:17351739 PMID:17510429 PMID:17620439 PMID:17626072 PMID:17659339 PMID:17898787 PMID:18005386 PMID:18641367 PMID:19100720 PMID:19261616 PMID:19417023 PMID:20051518 PMID:20442297 PMID:20471514 PMID:21345073 PMID:24291039 PMID:24377552 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression increases response to substance increases cleavage |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP9 protein; [Bortezomib co-treated with arsenic trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with arsenic trioxide] results in increased expression of CASP9 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with vorinostat] results in increased activity of CASP9 protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [vorinostat results in increased activity of CASP9 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein] Bortezomib results in increased expression of CASP9 protein CASP9 gene SNP results in increased susceptibility to Bortezomib; CASP9 results in increased susceptibility to Bortezomib |
CTD |
PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 PMID:16024631 PMID:16118318 PMID:16617327 PMID:16778179 PMID:16904634 PMID:16985072 PMID:17156654 PMID:17326159 PMID:17510429 PMID:17620439 PMID:17626072 PMID:17898295 PMID:17898787 PMID:18005386 PMID:18223231 PMID:18641367 PMID:18723477 PMID:19261616 PMID:19417023 PMID:20051518 PMID:20471514 PMID:20850924 PMID:20864405 PMID:21345073 PMID:21518486 PMID:24291039 PMID:24377552 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cbl |
Cbl proto-oncogene |
multiple interactions |
ISO |
[Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein] |
CTD |
PMID:19457607 |
|
NCBI chr 8:48,481,256...48,564,775
Ensembl chr 8:48,489,036...48,564,722
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
[Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of CBR3 mRNA |
CTD |
PMID:20806931 PMID:20977926 |
|
NCBI chr11:33,909,417...33,917,674
Ensembl chr11:33,909,439...33,917,674
|
|
G |
Cbx3 |
chromobox 3 |
increases expression |
ISO |
Bortezomib results in increased expression of CBX3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:81,243,809...81,257,898
Ensembl chr 4:81,244,469...81,257,897
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CCAR1 protein |
CTD |
PMID:21594647 PMID:21903591 |
|
NCBI chr20:32,373,443...32,416,044
Ensembl chr20:32,373,443...32,416,044
|
|
G |
Ccdc186 |
coiled-coil domain containing 186 |
increases expression |
ISO |
Bortezomib results in increased expression of CCDC186 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:277,603,601...277,635,379
Ensembl chr 1:277,606,995...277,629,196
|
|
G |
Ccdc32 |
coiled-coil domain containing 32 |
increases expression |
ISO |
Bortezomib results in increased expression of CCDC32 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:110,816,327...110,828,824
Ensembl chr 3:110,816,337...110,828,879
|
|
G |
Ccdc6 |
coiled-coil domain containing 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CCDC6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:19,729,005...19,825,219
Ensembl chr20:19,732,894...19,825,150
|
|
G |
Ccdc82 |
coiled-coil domain containing 82 |
increases expression |
ISO |
Bortezomib results in increased expression of CCDC82 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:11,888,460...11,927,920
Ensembl chr 8:11,888,591...11,927,919
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CCL2 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression decreases expression |
EXP ISO |
Bortezomib results in increased expression of CCL3 mRNA; Bortezomib results in increased expression of CCL3 protein Bortezomib results in decreased expression of CCL3 mRNA |
CTD |
PMID:18089816 PMID:20830808 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions increases expression |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; Bortezomib results in increased ubiquitination of and results in increased expression of CCNB1 protein Bortezomib results in increased expression of CCNB1 protein |
CTD |
PMID:19074855 PMID:20367638 PMID:25522274 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of CCND1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of CCND1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of CCND1 protein] |
CTD |
PMID:12893773 PMID:15173093 PMID:15781649 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CCND2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Ccnf |
cyclin F |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA |
CTD |
PMID:25522274 |
|
NCBI chr10:13,594,687...13,619,935
Ensembl chr10:13,594,687...13,619,935
|
|
G |
Ccng2 |
cyclin G2 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068
|
|
G |
Ccpg1 |
cell cycle progression 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CCPG1 mRNA |
CTD |
PMID:20471514 PMID:20977926 |
|
NCBI chr 8:79,660,634...79,692,044
Ensembl chr 8:79,660,657...79,692,039
|
|
G |
Cd27 |
CD27 molecule |
increases expression |
ISO |
Bortezomib results in increased expression of CD27 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 4:157,744,881...157,751,609
Ensembl chr 4:157,744,882...157,750,088
|
|
G |
Cd38 |
CD38 molecule |
decreases expression |
ISO |
Bortezomib results in decreased expression of CD38 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
|
|
G |
Cd5 |
Cd5 molecule |
decreases expression |
ISO |
Bortezomib results in decreased expression of CD5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:226,770,912...226,791,861
Ensembl chr 1:226,770,744...226,791,879
|
|
G |
Cd69 |
Cd69 molecule |
increases expression |
ISO |
Bortezomib results in increased expression of CD69 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084
|
|
G |
Cd79a |
CD79a molecule |
decreases expression |
ISO |
Bortezomib results in decreased expression of CD79A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:81,763,609...81,768,039
Ensembl chr 1:81,763,614...81,767,980
|
|
G |
Cd82 |
Cd82 molecule |
decreases expression |
ISO |
Bortezomib results in decreased expression of CD82 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:82,324,344...82,368,846
Ensembl chr 3:82,324,354...82,368,357
|
|
G |
Cd9 |
CD9 molecule |
increases expression |
ISO |
Bortezomib results in increased expression of CD9 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:157,977,163...158,010,091
Ensembl chr 4:157,977,162...158,010,166
|
|
G |
Cdc23 |
cell division cycle 23 |
increases expression |
ISO |
Bortezomib results in increased expression of CDC23 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:27,430,924...27,452,569
Ensembl chr18:27,430,905...27,452,420
|
|
G |
Cdc34 |
cell division cycle 34, ubiqiutin conjugating enzyme |
increases expression |
ISO |
Bortezomib results in increased expression of CDC34 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:12,899,957...12,905,339
Ensembl chr 7:12,899,958...12,905,339
|
|
G |
Cdc37 |
cell division cycle 37, HSP90 cochaperone |
increases expression |
ISO |
Bortezomib results in increased expression of CDC37 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 8:22,160,922...22,173,797
Ensembl chr 8:22,154,067...22,173,804
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CDC42 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:155,690,267...155,728,385
Ensembl chr 5:155,691,390...155,728,300
|
|
G |
Cdc42se2 |
CDC42 small effector 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CDC42SE2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:40,054,393...40,122,915
Ensembl chr10:40,054,400...40,122,915
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions increases phosphorylation increases activity decreases activity |
ISO |
Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK1 protein] Bortezomib results in increased phosphorylation of CDK1 protein Bortezomib results in increased activity of CDK1 protein Bortezomib results in decreased activity of CDK1 protein |
CTD |
PMID:14749476 PMID:16928825 PMID:19074855 PMID:20367638 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions decreases activity |
ISO |
Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK2 protein] Bortezomib results in decreased activity of CDK2 protein |
CTD |
PMID:14749476 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases stability multiple interactions decreases response to substance increases expression |
ISO |
Bortezomib results in increased stability of CDKN1A protein [Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with Butyrates] results in increased expression of and results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased expression of and results in increased cleavage of CDKN1A protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A mRNA; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1A protein; Bortezomib promotes the reaction [abexinostat results in increased expression of CDKN1A protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; CDKN1A results in decreased susceptibility to [Bortezomib co-treated with docetaxel] CDKN1A results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of CDKN1A mRNA; Bortezomib results in increased expression of CDKN1A protein |
CTD |
PMID:12893773 PMID:12902978 PMID:14749476 PMID:15173093 PMID:15543232 PMID:15930312 PMID:16928825 PMID:17327374 PMID:17898295 PMID:18223318 PMID:18445700 PMID:18790767 PMID:19220424 PMID:19417023 PMID:20383943 PMID:20977926 PMID:21345073 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions increases stability increases expression |
ISO |
[Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1B protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of CDKN1B protein; [Vorinostat co-treated with Bortezomib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Cisplatin promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein] Bortezomib results in increased stability of CDKN1B protein |
CTD |
PMID:14749476 PMID:15173093 PMID:15543232 PMID:18223318 PMID:18445700 PMID:18850583 PMID:19220424 PMID:19636294 PMID:20701607 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CDT1 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr19:55,381,565...55,386,511
Ensembl chr19:55,381,565...55,386,511
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein] |
CTD |
PMID:19662097 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions increases expression decreases expression |
ISO EXP |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Bortezomib inhibits the reaction [Arsenic Trioxide results in decreased expression of CEBPB mRNA]; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]] Bortezomib results in decreased expression of CEBPB mRNA |
CTD |
PMID:20471514 PMID:20830808 PMID:30482226 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Cenpc |
centromere protein C |
increases expression |
ISO |
Bortezomib results in increased expression of CENPC mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:23,611,909...23,670,314
Ensembl chr14:23,611,735...23,670,475
|
|
G |
Cep290 |
centrosomal protein 290 |
increases expression |
ISO |
Bortezomib results in increased expression of CEP290 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:40,217,269...40,306,327
Ensembl chr 7:40,217,269...40,306,327
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
affects expression multiple interactions decreases response to substance decreases expression increases expression |
ISO |
Bortezomib affects the expression of CFLAR protein [Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [romidepsin co-treated with Bortezomib] results in decreased expression of CFLAR protein; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein] CFLAR protein alternative form results in decreased susceptibility to Bortezomib; CFLAR results in decreased susceptibility to Bortezomib Bortezomib results in decreased expression of CFLAR mRNA; Bortezomib results in decreased expression of CFLAR protein Bortezomib results in increased expression of CFLAR protein; Bortezomib results in increased expression of CFLAR protein alternative form; Bortezomib results in increased expression of CFLAR protein modified form |
CTD |
PMID:17326159 PMID:17327374 PMID:17351739 PMID:17510429 PMID:17659339 PMID:18223231 PMID:19100720 PMID:19922463 PMID:20515944 PMID:20876774 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CGREF1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 6:26,797,126...26,809,132
Ensembl chr 6:26,797,126...26,809,129
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CHAC1 mRNA |
CTD |
PMID:15509775 |
|
NCBI chr 3:111,160,205...111,163,425
Ensembl chr 3:111,160,205...111,163,425
|
|
G |
Chaf1a |
chromatin assembly factor 1 subunit A |
decreases expression |
ISO |
Bortezomib results in decreased expression of CHAF1A mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 9:11,000,869...11,027,631
Ensembl chr 9:11,001,129...11,027,506
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
increases expression |
ISO |
Bortezomib results in increased expression of CHD2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:134,757,934...134,873,053
Ensembl chr 1:134,757,934...134,871,167
|
|
G |
Chfr |
checkpoint with forkhead and ring finger domains |
decreases expression |
ISO |
Bortezomib results in decreased expression of CHFR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:52,562,594...52,596,162
Ensembl chr12:52,562,597...52,596,076
|
|
G |
Chst11 |
carbohydrate sulfotransferase 11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CHST11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:26,641,856...26,890,503
Ensembl chr 7:26,645,422...26,859,716
|
|
G |
Chst2 |
carbohydrate sulfotransferase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CHST2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:103,186,759...103,190,612
Ensembl chr 8:103,188,651...103,190,243
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases expression increases activity |
ISO |
Bortezomib results in increased expression of CHUK mRNA Bortezomib results in increased activity of CHUK protein |
CTD |
PMID:20471514 PMID:24085292 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Cideb |
cell death-inducing DFFA-like effector b |
decreases expression |
ISO |
Bortezomib results in decreased expression of CIDEB mRNA |
CTD |
PMID:17659339 |
|
NCBI chr15:34,439,844...34,444,244
Ensembl chr15:34,439,876...34,444,244
|
|
G |
Cilk1 |
ciliogenesis associated kinase 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CILK1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:85,413,998...85,473,374
Ensembl chr 8:85,413,537...85,472,694
|
|
G |
Clec7a |
C-type lectin domain containing 7A |
increases expression |
ISO |
Bortezomib results in increased expression of CLEC7A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:163,216,152...163,227,367
Ensembl chr 4:163,216,163...163,227,334
|
|
G |
Clip4 |
CAP-GLY domain containing linker protein family, member 4 |
increases expression |
ISO |
Bortezomib results in increased expression of CLIP4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:23,222,020...23,316,962
Ensembl chr 6:23,222,021...23,316,962
|
|
G |
Cln6 |
CLN6, transmembrane ER protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of CLN6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:67,733,215...67,748,170
Ensembl chr 8:67,733,215...67,748,172
|
|
G |
Clptm1 |
CLPTM1 regulator of GABA type A receptor forward trafficking |
decreases expression |
ISO |
Bortezomib results in decreased expression of CLPTM1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:80,549,051...80,580,665
Ensembl chr 1:80,549,043...80,580,662
|
|
G |
Clu |
clusterin |
increases expression |
ISO |
Bortezomib results in increased expression of CLU mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
|
|
G |
Cox8a |
cytochrome c oxidase subunit 8A |
decreases expression |
ISO |
Bortezomib results in decreased expression of COX8A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr 1:222,466,575...222,468,896
Ensembl chr 1:222,466,575...222,468,896
|
|
G |
Cpt1c |
carnitine palmitoyltransferase 1c |
increases response to substance |
ISO |
CPT1C gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr 1:100,955,094...100,970,579
Ensembl chr 1:100,955,095...100,969,560
|
|
G |
Crebbp |
CREB binding protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of CREBBP mRNA |
CTD |
PMID:25913414 |
|
NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039
|
|
G |
Crem |
cAMP responsive element modulator |
increases expression |
ISO |
Bortezomib results in increased expression of CREM mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
|
|
G |
Crip2 |
cysteine-rich protein 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CRIP2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:137,953,545...137,958,491
Ensembl chr 6:137,953,545...137,958,490
|
|
G |
Crkl |
CRK like proto-oncogene, adaptor protein |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein |
CTD |
PMID:15039284 |
|
NCBI chr11:87,338,606...87,356,644
Ensembl chr11:87,778,312...87,815,043
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions increases expression |
ISO EXP |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA Bortezomib results in increased expression of CRYAB mRNA |
CTD |
PMID:20830808 PMID:25522274 |
|
NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545
|
|
G |
Cst7 |
cystatin F |
increases expression |
ISO |
Bortezomib results in increased expression of CST7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:146,363,913...146,373,365
Ensembl chr 3:146,365,092...146,373,365
|
|
G |
Ctdspl2 |
CTD small phosphatase like 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CTDSPL2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:113,906,803...113,957,289
Ensembl chr 3:113,918,629...113,960,101
|
|
G |
Cth |
cystathionine gamma-lyase |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions decreases response to substance increases expression |
ISO |
2-methoxyestradiol inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; arsenic trioxide inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein] |
CTD |
PMID:18485479 PMID:19100720 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctsb |
cathepsin B |
multiple interactions increases localization |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased localization of CTSB protein] |
CTD |
PMID:16446371 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Ctsd |
cathepsin D |
increases expression |
ISO |
Bortezomib results in increased expression of CTSD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Cul1 |
cullin 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CUL1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 4:77,211,814...77,283,369
Ensembl chr 4:77,211,692...77,280,250
|
|
G |
Cul3 |
cullin 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CUL3 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 9:86,044,485...86,129,066
Ensembl chr 9:86,044,485...86,129,329
|
|
G |
Cwf19l1 |
CWF19 like cell cycle control factor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CWF19L1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:263,887,014...263,910,251
Ensembl chr 1:263,887,015...263,910,251
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CXCL1 mRNA |
CTD |
PMID:15509775 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO EXP |
Bortezomib results in increased expression of CXCL2 mRNA Bortezomib results in increased expression of CXCL2 mRNA; Bortezomib results in increased expression of CXCL2 protein Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL2 mRNA] |
CTD |
PMID:20830808 PMID:27194111 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
ISO |
Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL1 mRNA] Bortezomib results in increased expression of CXCL1 mRNA |
CTD |
PMID:15509775 PMID:27194111 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CXCR4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CYB5R1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:51,229,697...51,236,447
Ensembl chr13:51,229,890...51,236,463
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression |
ISO |
Bortezomib results in decreased expression of CYBA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions affects localization |
ISO |
[Bortezomib co-treated with Butyrates] affects the localization of CYCS protein; [Bortezomib co-treated with vorinostat] affects the localization of CYCS protein Bortezomib affects the localization of CYCS protein |
CTD |
PMID:12893773 PMID:16024631 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects metabolic processing |
ISO |
CYP1A2 protein affects the metabolism of Bortezomib |
CTD |
PMID:15764713 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
affects metabolic processing |
ISO |
CYP2C9 protein affects the metabolism of Bortezomib |
CTD |
PMID:15764713 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
affects metabolic processing |
ISO |
CYP2C19 protein affects the metabolism of Bortezomib |
CTD |
PMID:15764713 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects metabolic processing |
ISO |
CYP2D6 protein affects the metabolism of Bortezomib |
CTD |
PMID:15764713 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2u1 |
cytochrome P450, family 2, subfamily u, polypeptide 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CYP2U1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:236,414,131...236,431,650
Ensembl chr 2:236,414,135...236,431,683
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
affects metabolic processing |
ISO |
CYP3A4 protein affects the metabolism of Bortezomib |
CTD |
PMID:15764713 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cytip |
cytohesin 1 interacting protein |
increases expression |
ISO |
Bortezomib results in increased expression of CYTIP mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:44,150,494...44,225,723
Ensembl chr 3:44,150,992...44,177,689
|
|
G |
Dap3 |
death associated protein 3 |
increases expression |
ISO |
Bortezomib results in increased expression of DAP3 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 2:188,225,607...188,255,324
Ensembl chr 2:188,225,613...188,252,725
|
|
G |
Dapk2 |
death-associated protein kinase 2 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 8:71,822,107...71,941,941
Ensembl chr 8:71,822,129...71,941,910
|
|
G |
Dazap2 |
DAZ associated protein 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DAZAP2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:142,238,780...142,244,301
Ensembl chr 7:142,239,035...142,243,241
|
|
G |
Dbn1 |
drebrin 1 |
increases expression |
ISO |
Bortezomib results in increased expression of DBN1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:9,679,511...9,693,878
Ensembl chr17:9,679,628...9,693,820
|
|
G |
Dcaf11 |
DDB1 and CUL4 associated factor 11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DCAF11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:34,233,840...34,244,512
Ensembl chr15:34,234,193...34,244,504
|
|
G |
Dcaf13 |
DDB1 and CUL4 associated factor 13 |
increases expression |
ISO |
Bortezomib results in increased expression of DCAF13 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:78,005,232...78,040,220
Ensembl chr 7:78,005,232...78,040,214
|
|
G |
Dcps |
decapping enzyme, scavenger |
decreases expression |
ISO |
Bortezomib results in decreased expression of DCPS mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:36,321,992...36,374,665
Ensembl chr 8:36,321,993...36,374,673
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression decreases response to substance |
ISO EXP |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of DDIT3 protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of DDIT3 protein] Bortezomib results in increased expression of DDIT3 mRNA; Bortezomib results in increased expression of DDIT3 protein 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; [Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Nitroprusside inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein] DDIT3 results in decreased susceptibility to Bortezomib |
CTD |
PMID:15509775 PMID:16024631 PMID:16357177 PMID:17659339 PMID:17709599 PMID:17898295 PMID:18723477 PMID:20022965 PMID:20110775 PMID:20830808 PMID:22959925 PMID:24291039 PMID:30482226 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddx11 |
DEAD/H-box helicase 11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DDX11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:114,113,642...114,133,908
Ensembl chr 9:114,111,580...114,132,492
|
|
G |
Deaf1 |
DEAF1 transcription factor |
decreases expression |
ISO |
Bortezomib results in decreased expression of DEAF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:214,283,787...214,317,466
Ensembl chr 1:214,283,790...214,317,466
|
|
G |
Dedd2 |
death effector domain containing 2 |
increases expression |
ISO |
Bortezomib results in increased expression of DEDD2 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 1:82,073,024...82,089,028
Ensembl chr 1:82,072,544...82,088,275
|
|
G |
Def6 |
DEF6 guanine nucleotide exchange factor |
decreases expression |
ISO |
Bortezomib results in decreased expression of DEF6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:7,788,120...7,809,011
Ensembl chr20:7,788,084...7,809,560
|
|
G |
Dennd4a |
DENN domain containing 4A |
increases expression |
ISO |
Bortezomib results in increased expression of DENND4A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:70,293,355...70,406,675
Ensembl chr 8:70,317,586...70,406,751
|
|
G |
Dennd4b |
DENN domain containing 4B |
increases expression |
ISO |
Bortezomib results in increased expression of DENND4B mRNA |
CTD |
PMID:15509775 |
|
NCBI chr 2:189,626,922...189,642,732
Ensembl chr 2:189,629,297...189,642,183
|
|
G |
Dennd4c |
DENN domain containing 4C |
increases expression |
ISO |
Bortezomib results in increased expression of DENND4C mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:105,100,081...105,195,634
Ensembl chr 5:105,114,433...105,193,988
|
|
G |
Dgke |
diacylglycerol kinase epsilon |
decreases expression |
ISO |
Bortezomib results in decreased expression of DGKE mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:76,375,981...76,408,224
Ensembl chr10:76,386,471...76,407,989
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
affects localization increases localization increases expression multiple interactions |
ISO |
Bortezomib affects the localization of DIABLO protein Bortezomib results in increased localization of DIABLO protein Bortezomib results in increased expression of DIABLO mRNA; Bortezomib results in increased expression of DIABLO protein [alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in decreased localization of DIABLO protein; [Bortezomib co-treated with Butyrates] affects the localization of DIABLO protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib co-treated with vorinostat] affects the localization of DIABLO protein; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein] |
CTD |
PMID:12893773 PMID:12902978 PMID:14555532 PMID:15039284 PMID:15070698 PMID:16024631 PMID:17327374 PMID:25913414 |
|
NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
|
|
G |
Dlgap5 |
DLG associated protein 5 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr15:24,167,484...24,199,417
Ensembl chr15:24,167,486...24,199,341
|
|
G |
Dnaaf5 |
dynein, axonemal, assembly factor 5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DNAAF5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:17,545,468...17,584,466
Ensembl chr12:17,545,468...17,584,466
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
increases expression |
ISO |
Bortezomib results in increased expression of DNAJB1 mRNA |
CTD |
PMID:15509775 |
|
NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
|
|
G |
Dnajc14 |
DnaJ heat shock protein family (Hsp40) member C14 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DNAJC14 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:3,229,026...3,242,265
Ensembl chr 7:3,230,320...3,242,265
|
|
G |
Dnajc4 |
DnaJ heat shock protein family (Hsp40) member C4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DNAJC4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:222,242,889...222,247,115
Ensembl chr 1:222,242,858...222,246,768
|
|
G |
Dnm2 |
dynamin 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DNM2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:22,458,869...22,540,649
Ensembl chr 8:22,458,899...22,540,524
|
|
G |
Dpy19l4 |
dpy-19 like 4 |
increases expression |
ISO |
Bortezomib results in increased expression of DPY19L4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:24,503,074...24,560,077
Ensembl chr 5:24,504,614...24,560,063
|
|
G |
Dst |
dystonin |
increases expression |
ISO |
Bortezomib results in increased expression of DST mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 9:37,902,336...38,296,961
Ensembl chr 9:37,902,303...38,196,273
|
|
G |
Dusp15 |
dual specificity phosphatase 15 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DUSP15 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:148,417,990...148,428,494
Ensembl chr 3:148,417,993...148,428,494
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DUSP4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:61,080,767...61,090,973
Ensembl chr16:61,078,175...61,091,169
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 1:274,245,184...274,258,595
Ensembl chr 1:274,245,184...274,258,595
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
increases expression |
ISO |
Bortezomib results in increased expression of DYNC1I1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:30,807,755...31,121,097
Ensembl chr 4:30,807,879...31,121,090
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein |
CTD |
PMID:25522274 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
Ecpas |
Ecm29 proteasome adaptor and scaffold |
increases expression |
ISO |
Bortezomib results in increased expression of ECPAS mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:75,928,510...76,040,771
Ensembl chr 5:75,931,293...76,039,760
|
|
G |
Edaradd |
EDAR-associated death domain |
increases expression |
ISO |
Bortezomib results in increased expression of EDARADD mRNA |
CTD |
PMID:17895889 |
|
NCBI chr17:90,802,280...90,843,476
Ensembl chr17:90,802,393...90,843,485
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 6:75,050,329...75,075,795
Ensembl chr 6:75,050,329...75,075,795
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Bortezomib results in increased expression of EGR1 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Egr2 |
early growth response 2 |
decreases expression |
ISO EXP |
Bortezomib results in decreased expression of EGR2 mRNA Bortezomib results in decreased expression of EGR2 mRNA; Bortezomib results in decreased expression of EGR2 protein |
CTD |
PMID:20830808 |
|
NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
|
|
G |
Ehmt2 |
euchromatic histone lysine methyltransferase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of EHMT2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:4,576,033...4,592,980
Ensembl chr20:4,576,057...4,592,980
|
|
G |
Eif1 |
eukaryotic translation initiation factor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of EIF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:88,227,455...88,229,546
Ensembl chr10:88,227,360...88,229,765
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
decreases phosphorylation |
ISO |
Bortezomib results in decreased phosphorylation of EIF2A protein |
CTD |
PMID:18641367 |
|
NCBI chr 2:148,722,343...148,755,781
Ensembl chr 2:148,722,231...148,755,520
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation multiple interactions decreases response to substance |
ISO |
Bortezomib results in increased phosphorylation of EIF2AK3 protein Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]] EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein] EIF2AK3 results in decreased susceptibility to Bortezomib |
CTD |
PMID:15509775 PMID:16928686 PMID:20022965 PMID:22959925 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
Bortezomib inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:16357177 PMID:20022965 PMID:21090173 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Eif2s3 |
eukaryotic translation initiation factor 2 subunit gamma |
decreases expression |
ISO |
Bortezomib results in decreased expression of EIF2S3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:63,268,106...63,291,125
Ensembl chr X:63,268,037...63,292,092
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[trichostatin A co-treated with Bortezomib] results in decreased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:21345073 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
decreases expression |
ISO |
Bortezomib results in decreased expression of EIF5A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:56,527,075...56,531,615
Ensembl chr10:56,527,085...56,531,483
|
|
G |
Elp5 |
elongator acetyltransferase complex subunit 5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ELP5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:56,578,980...56,590,706
Ensembl chr10:56,578,985...56,591,364
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
Bortezomib results in increased expression of ENO2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
Epha1 |
Eph receptor A1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of EPHA1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:71,749,100...71,763,681
Ensembl chr 4:71,749,242...71,763,679
|
|
G |
Ephb2 |
Eph receptor B2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of EPHB2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:155,024,478...155,143,539
Ensembl chr 5:155,022,493...155,204,456
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases phosphorylation |
ISO |
Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein]; lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein] |
CTD |
PMID:20701607 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Ercc3 |
ERCC excision repair 3, TFIIH core complex helicase subunit |
increases response to substance |
ISO |
ERCC3 gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr18:25,037,668...25,068,380
Ensembl chr18:25,037,625...25,068,389
|
|
G |
Ercc4 |
ERCC excision repair 4, endonuclease catalytic subunit |
increases response to substance |
ISO |
ERCC4 gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr10:2,010,140...2,037,953
Ensembl chr10:2,010,648...2,037,891
|
|
G |
Erlin2 |
ER lipid raft associated 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ERLIN2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:69,179,005...69,195,452
Ensembl chr16:69,179,588...69,195,097
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions decreases response to substance |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA ERN1 results in decreased susceptibility to Bortezomib |
CTD |
PMID:16357177 PMID:25522274 |
|
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
|
|
G |
Esf1 |
ESF1 nucleolar pre-rRNA processing protein homolog |
increases expression |
ISO |
Bortezomib results in increased expression of ESF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:133,178,591...133,232,358
Ensembl chr 3:133,178,561...133,232,322
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Bortezomib binds to and results in decreased activity of ESR1 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:25752796 PMID:30818834 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
[Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ESR2 mRNA; Bortezomib binds to and results in decreased activity of ESR2 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein] |
CTD |
PMID:25752796 PMID:25913414 PMID:30818834 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of ESRRA mRNA Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; Bortezomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:20977926 PMID:30818834 |
|
NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
|
|
G |
Esyt2 |
extended synaptotagmin 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ESYT2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:144,156,021...144,248,374
Ensembl chr 6:144,156,175...144,245,545
|
|
G |
Etv4 |
ETS variant transcription factor 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ETV4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:89,685,058...89,700,300
Ensembl chr10:89,685,058...89,700,283
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of F2RL1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:25,222,324...25,235,275
Ensembl chr 2:25,222,328...25,235,275
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of F3 protein [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein |
CTD |
PMID:23696885 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fads2 |
fatty acid desaturase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FADS2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
|
|
G |
Faf1 |
Fas associated factor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of FAF1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 5:129,370,767...129,738,393
Ensembl chr 5:129,448,879...129,738,252
|
|
G |
Fam118b |
family with sequence similarity 118, member B |
increases expression |
ISO |
Bortezomib results in increased expression of FAM118B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:36,416,769...36,467,609
Ensembl chr 8:36,416,997...36,467,627
|
|
G |
Fam168a |
family with sequence similarity 168, member A |
increases expression |
ISO |
Bortezomib results in increased expression of FAM168A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:165,723,278...165,880,612
Ensembl chr 1:165,724,451...165,878,652
|
|
G |
Fam20b |
FAM20B, glycosaminoglycan xylosylkinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of FAM20B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:74,280,173...74,333,463
Ensembl chr13:74,280,173...74,331,214
|
|
G |
Fam219a |
family with sequence similarity 219, member A |
increases expression |
ISO |
Bortezomib results in increased expression of FAM219A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:57,896,824...57,947,569
Ensembl chr 5:57,897,368...57,947,183
|
|
G |
Fam241b |
family with sequence similarity 241 member B |
increases expression |
ISO |
Bortezomib results in increased expression of FAM241B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:31,734,297...31,736,115
Ensembl chr20:31,734,183...31,736,212
|
|
G |
Fam43a |
family with sequence similarity 43, member A |
decreases expression |
ISO |
Bortezomib results in decreased expression of FAM43A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:73,676,601...73,679,003
Ensembl chr11:73,676,601...73,678,984
|
|
G |
Fam76a |
family with sequence similarity 76, member A |
increases expression |
ISO |
Bortezomib results in increased expression of FAM76A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:151,087,962...151,117,142
Ensembl chr 5:151,089,900...151,117,042
|
|
G |
Fancd2 |
FA complementation group D2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FANCD2 mRNA; Bortezomib results in decreased expression of FANCD2 protein |
CTD |
PMID:19934314 PMID:21917757 |
|
NCBI chr 4:145,489,869...145,551,479
Ensembl chr 4:145,489,869...145,551,479
|
|
G |
Farsa |
phenylalanyl-tRNA synthetase subunit alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of FARSA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:25,969,255...25,978,777
Ensembl chr19:25,969,255...25,978,776
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions decreases expression increases expression |
ISO |
[Bortezomib co-treated with vorinostat] results in increased expression of FAS protein Bortezomib results in decreased expression of FAS mRNA Bortezomib results in increased expression of FAS mRNA; Bortezomib results in increased expression of FAS protein |
CTD |
PMID:17351739 PMID:20471514 PMID:25913414 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
ISO |
[Bortezomib co-treated with vorinostat] results in increased expression of FASLG mRNA; [Bortezomib co-treated with vorinostat] results in increased expression of FASLG protein; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of FASLG]; Curcumin inhibits the reaction [[vorinostat co-treated with Bortezomib] results in increased expression of FASLG protein] Bortezomib results in increased expression of FASLG protein |
CTD |
PMID:17351739 PMID:20471514 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fastk |
Fas-activated serine/threonine kinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of FASTK mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:7,260,521...7,264,590
Ensembl chr 4:7,260,575...7,264,589
|
|
G |
Fbln5 |
fibulin 5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FBLN5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:125,644,797...125,723,957
Ensembl chr 6:125,644,804...125,723,944
|
|
G |
Fbxw7 |
F-box and WD repeat domain containing 7 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FBXW7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:184,230,191...184,309,805
Ensembl chr 2:184,231,260...184,309,664
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 1:101,595,579...101,596,822
Ensembl chr 1:101,595,579...101,596,822
|
|
G |
Fgfr1op2 |
FGFR1 oncogene partner 2 |
increases expression |
ISO |
Bortezomib results in increased expression of FGFR1OP2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:180,887,182...180,908,206
Ensembl chr 4:180,887,182...180,908,198
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
decreases expression |
ISO |
Bortezomib results in decreased expression of FKBP1A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:147,042,944...147,062,725
Ensembl chr 3:147,042,944...147,062,724
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FKBP5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:7,976,704...8,097,290
Ensembl chr20:7,976,713...8,019,020
|
|
G |
Flcn |
folliculin |
increases expression |
ISO |
Bortezomib results in increased expression of FLCN mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:46,153,185...46,172,331
Ensembl chr10:46,153,188...46,172,309
|
|
G |
Fmr1 |
FMRP translational regulator 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FMR1 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr X:154,684,924...154,722,369
Ensembl chr X:154,684,935...154,722,314
|
|
G |
Folr1 |
folate receptor alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of FOLR1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:166,934,457...166,945,864
Ensembl chr 1:166,934,460...166,943,592
|
|
G |
Foxa1 |
forkhead box A1 |
multiple interactions decreases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in increased expression of FOXA1 mRNA Bortezomib results in decreased expression of FOXA1 mRNA |
CTD |
PMID:20471514 PMID:25913414 |
|
NCBI chr 6:78,516,579...78,549,669
Ensembl chr 6:78,545,804...78,549,669
|
|
G |
Fry |
FRY microtubule binding protein |
increases expression |
ISO |
Bortezomib results in increased expression of FRY mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:5,573,729...5,822,874
Ensembl chr12:5,573,729...5,822,874
|
|
G |
Fsd1l |
fibronectin type III and SPRY domain containing 1-like |
increases expression |
ISO |
Bortezomib results in increased expression of FSD1L mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:70,441,075...70,517,131
Ensembl chr 5:70,441,123...70,511,659
|
|
G |
Fzd2 |
frizzled class receptor 2 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr10:90,550,147...90,552,057
Ensembl chr10:90,550,147...90,552,057
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases expression |
ISO |
Bortezomib results in decreased expression of G6PD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:156,274,800...156,293,935
Ensembl chr X:156,274,800...156,293,926
|
|
G |
Gabarapl1 |
GABA type A receptor associated protein like 1 |
increases expression |
ISO |
Bortezomib results in increased expression of GABARAPL1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:163,293,724...163,302,866
Ensembl chr 4:163,293,724...163,302,858
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression multiple interactions |
ISO EXP |
Bortezomib results in increased expression of GADD45A mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA |
CTD |
PMID:20830808 PMID:20977926 PMID:25522274 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of GADD45B mRNA Bortezomib inhibits the reaction [lipopolysaccharide A results in increased expression of GADD45B mRNA] |
CTD |
PMID:15509775 PMID:15797874 PMID:17895889 PMID:17898295 |
|
NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
increases expression |
ISO |
Bortezomib results in increased expression of GADD45G mRNA |
CTD |
PMID:17898295 |
|
NCBI chr17:13,391,474...13,393,219
Ensembl chr17:13,391,467...13,393,243
|
|
G |
Galnt4 |
polypeptide N-acetylgalactosaminyltransferase 4 |
increases expression |
ISO |
Bortezomib results in increased expression of GALNT4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:41,305,437...41,309,621
|
|
G |
Ganab |
glucosidase II alpha subunit |
decreases expression |
ISO |
Bortezomib results in decreased expression of GANAB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:225,096,558...225,116,384
Ensembl chr 1:225,096,598...225,116,378
|
|
G |
Gas7 |
growth arrest specific 7 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GAS7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:54,010,723...54,240,805
Ensembl chr10:54,126,486...54,236,476
|
|
G |
Gbp2 |
guanylate binding protein 2 |
increases expression |
ISO |
Bortezomib results in increased expression of GBP2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:248,276,795...248,293,784
Ensembl chr 2:248,276,709...248,293,784
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 (I blood group) |
increases expression |
ISO |
Bortezomib results in increased expression of GCNT2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:21,634,546...21,677,477
Ensembl chr17:21,634,551...21,739,408
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression multiple interactions |
EXP ISO |
Bortezomib results in increased expression of GDF15 mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA |
CTD |
PMID:20830808 PMID:25522274 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Ghr |
growth hormone receptor |
increases expression |
ISO |
Bortezomib results in increased expression of GHR mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 2:53,149,225...53,413,954
Ensembl chr 2:53,150,370...53,413,638
|
|
G |
Git1 |
GIT ArfGAP 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GIT1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:62,656,000...62,664,467
Ensembl chr10:62,656,000...62,664,466
|
|
G |
Gkap1 |
G kinase anchoring protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of GKAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:6,785,428...6,825,145
Ensembl chr17:6,785,428...6,825,144
|
|
G |
Gla |
galactosidase, alpha |
increases expression |
ISO |
Bortezomib results in increased expression of GLA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:105,405,915...105,417,331
Ensembl chr X:105,406,792...105,417,323
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
increases expression |
ISO |
Bortezomib results in increased expression of GNAI3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:210,896,779...210,934,733
Ensembl chr 2:210,896,656...210,934,749
|
|
G |
Gosr2 |
golgi SNAP receptor complex member 2 |
increases expression |
ISO |
Bortezomib results in increased expression of GOSR2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:91,735,772...91,756,123
Ensembl chr10:91,736,780...91,756,081
|
|
G |
Gpank1 |
G patch domain and ankyrin repeats 1 |
increases expression |
ISO |
Bortezomib results in increased expression of GPANK1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:5,113,232...5,116,382
Ensembl chr20:5,113,339...5,116,382
|
|
G |
Gpat3 |
glycerol-3-phosphate acyltransferase 3 |
increases expression |
ISO |
Bortezomib results in increased expression of GPAT3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:10,343,287...10,396,565
Ensembl chr14:10,343,282...10,395,047
|
|
G |
Gpatch2l |
G patch domain containing 2-like |
increases expression |
ISO |
Bortezomib results in increased expression of GPATCH2L mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:110,093,767...110,228,943
Ensembl chr 6:110,093,819...110,227,475
|
|
G |
Gphn |
gephyrin |
decreases expression |
ISO |
Bortezomib results in decreased expression of GPHN mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:101,327,874...101,859,169
Ensembl chr 6:101,532,518...101,859,164
|
|
G |
Gpr157 |
G protein-coupled receptor 157 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GPR157 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:167,109,691...167,125,380
Ensembl chr 5:167,109,691...167,125,380
|
|
G |
Gpsm3 |
G-protein signaling modulator 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GPSM3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:4,355,246...4,357,107
Ensembl chr20:4,355,175...4,357,107
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
multiple interactions |
ISO |
[Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3A protein modified form |
CTD |
PMID:16118318 |
|
NCBI chr 1:82,097,244...82,108,238
Ensembl chr 1:82,097,247...82,108,203
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3B protein modified form; Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:16118318 PMID:24085292 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gspt1 |
G1 to S phase transition 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GSPT1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:4,313,100...4,347,661
Ensembl chr10:4,312,863...4,446,200
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression |
ISO |
Bortezomib results in increased expression of GSR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gstcd |
glutathione S-transferase, C-terminal domain containing |
decreases expression |
ISO |
Bortezomib results in decreased expression of GSTCD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:238,109,758...238,253,326
Ensembl chr 2:238,109,490...238,253,287
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GSTM4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:210,834,013...210,839,242
Ensembl chr 2:210,833,884...210,839,295
|
|
G |
Gtf3c2 |
general transcription factor IIIC subunit 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GTF3C2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:26,560,601...26,584,533
Ensembl chr 6:26,560,601...26,584,535
|
|
G |
Gtpbp1 |
GTP binding protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GTPBP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:120,923,274...120,947,723
Ensembl chr 7:120,923,274...120,947,723
|
|
G |
Gzma |
granzyme A |
decreases expression |
ISO |
Bortezomib results in decreased expression of GZMA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:44,968,846...44,981,436
Ensembl chr 2:44,968,765...44,981,458
|
|
G |
Gzmb |
granzyme B |
increases expression |
ISO |
Bortezomib results in increased expression of GZMB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:35,413,862...35,417,293
Ensembl chr15:35,413,793...35,417,316
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions decreases phosphorylation increases expression |
ISO EXP |
[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein]; leptomycin B promotes the reaction [Bortezomib results in increased expression of H2AX protein modified form] Bortezomib results in decreased phosphorylation of H2AX protein Bortezomib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein] |
CTD |
PMID:15173094 PMID:16778179 PMID:17875725 PMID:18790767 PMID:32482060 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
H6pd |
hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) |
decreases expression |
ISO |
Bortezomib results in decreased expression of H6PD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:166,994,683...167,030,441
Ensembl chr 5:166,998,881...167,030,441
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
increases expression |
ISO |
Bortezomib results in increased expression of HADHA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:27,589,840...27,628,921
Ensembl chr 6:27,589,657...27,629,175
|
|
G |
Hdac10 |
histone deacetylase 10 |
decreases expression |
ISO |
Bortezomib results in decreased expression of HDAC10 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:130,102,335...130,109,036
Ensembl chr 7:130,102,347...130,107,437
|
|
G |
Hdac4 |
histone deacetylase 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of HDAC4 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 9:99,052,945...99,299,715
Ensembl chr 9:99,057,089...99,299,715
|
|
G |
Hdac6 |
histone deacetylase 6 |
decreases response to substance |
ISO |
HDAC6 results in decreased susceptibility to Bortezomib |
CTD |
PMID:16585204 |
|
NCBI chr X:15,295,372...15,316,673
Ensembl chr X:15,295,473...15,316,671
|
|
G |
Hectd2 |
HECT domain E3 ubiquitin protein ligase 2 |
increases expression |
ISO |
Bortezomib results in increased expression of HECTD2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:255,186,729...255,254,307
Ensembl chr 1:255,185,629...255,254,307
|
|
G |
Hecw1 |
HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr17:53,229,997...53,777,474
Ensembl chr17:53,229,785...53,773,657
|
|
G |
Hexd |
hexosaminidase D |
decreases expression |
ISO |
Bortezomib results in decreased expression of HEXD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:110,406,431...110,425,042
Ensembl chr10:110,406,450...110,425,042
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Bortezomib results in increased expression of HIF1A protein |
CTD |
PMID:16061869 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hikeshi |
heat shock protein nuclear import factor |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 1:154,147,098...154,170,429
Ensembl chr 1:154,142,836...154,170,409
|
|
G |
Hist1h2ail1 |
histone cluster 1 H2a family member I like 1 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr17:43,814,773...43,815,183
Ensembl chr17:43,814,773...43,815,183 Ensembl chr17:43,814,773...43,815,183
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases response to substance increases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of HMOX1 mRNA; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in increased susceptibility to Bortezomib; abexinostat promotes the reaction [Bortezomib results in increased expression of HMOX1 mRNA] HMOX1 protein results in increased susceptibility to Bortezomib Bortezomib results in increased expression of HMOX1 mRNA; Bortezomib results in increased expression of HMOX1 protein |
CTD |
PMID:15509775 PMID:17895889 PMID:19417023 PMID:20471514 PMID:25913414 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hmox2 |
heme oxygenase 2 |
multiple interactions |
ISO |
abexinostat promotes the reaction [Bortezomib results in decreased expression of HMOX2 mRNA] |
CTD |
PMID:19417023 |
|
NCBI chr10:10,990,034...11,035,493
Ensembl chr10:10,990,034...11,035,484
|
|
G |
Hnrnpll |
heterogeneous nuclear ribonucleoprotein L-like |
increases expression |
ISO |
Bortezomib results in increased expression of HNRNPLL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:2,698,983...2,729,715
Ensembl chr 6:2,699,961...2,729,394
|
|
G |
Hoxa11 |
homeobox A11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of HOXA11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:82,296,888...82,301,419
Ensembl chr 4:82,298,152...82,300,503 Ensembl chr 4:82,298,152...82,300,503
|
|
G |
Hps3 |
HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of HPS3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:104,789,423...104,832,964
Ensembl chr 2:104,789,423...104,830,898
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:22842577 |
|
NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of HSF1 mRNA Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter] |
CTD |
PMID:17895889 PMID:23874968 |
|
NCBI chr 7:117,538,523...117,565,478
Ensembl chr 7:117,538,523...117,565,478
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
increases expression decreases expression |
ISO EXP |
Bortezomib results in increased expression of HSP90AA1 mRNA Bortezomib results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:17895889 PMID:20471514 PMID:20830808 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
increases expression |
ISO |
Bortezomib results in increased expression of HSP90AB1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 9:17,817,791...17,823,163
Ensembl chr 9:17,817,721...17,823,243
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions decreases response to substance increases expression |
ISO |
Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter] HSPA1A protein results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of HSPA1A mRNA |
CTD |
PMID:17895889 PMID:23874968 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
increases expression affects response to substance decreases response to substance |
ISO |
Bortezomib results in increased expression of HSPA1B mRNA HSPA1B protein affects the susceptibility to Bortezomib HSPA1B protein results in decreased susceptibility to Bortezomib |
CTD |
PMID:15509775 PMID:17895889 PMID:23874968 |
|
NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
|
|
G |
Hspa4l |
heat shock protein family A (Hsp70) member 4 like |
increases expression |
EXP |
Bortezomib results in increased expression of HSPA4L mRNA |
CTD |
PMID:20830808 |
|
NCBI chr 2:127,625,737...127,682,864
Ensembl chr 2:127,625,683...127,677,503
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression decreases response to substance |
ISO |
Bortezomib inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [geldanamycin results in increased expression of HSPA5 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; geldanamycin promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein] Bortezomib results in increased expression of HSPA5 mRNA HSPA5 results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of HSPA5; Bortezomib results in increased expression of HSPA5 mRNA; Bortezomib results in increased expression of HSPA5 protein |
CTD |
PMID:15141013 PMID:15509775 PMID:16024631 PMID:16357177 PMID:18641367 PMID:18723477 PMID:20110775 PMID:20546536 PMID:20977926 PMID:21762082 PMID:24291039 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression decreases response to substance |
EXP ISO |
Bortezomib results in increased expression of HSPB1 mRNA HSPB1 protein results in decreased susceptibility to Bortezomib |
CTD |
PMID:14559800 PMID:20830808 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression |
ISO |
Bortezomib results in increased expression of HSPH1 mRNA |
CTD |
PMID:17898295 |
|
NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
|
|
G |
Htr2b |
5-hydroxytryptamine receptor 2B |
decreases expression |
ISO |
Bortezomib results in decreased expression of HTR2B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:93,112,781...93,130,135
Ensembl chr 9:93,112,805...93,125,014
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
affects localization |
ISO |
Bortezomib affects the localization of HTRA2 protein |
CTD |
PMID:16024631 |
|
NCBI chr 4:113,883,671...113,886,833
Ensembl chr 4:113,883,670...113,886,994
|
|
G |
Ibtk |
inhibitor of Bruton tyrosine kinase |
increases expression |
ISO |
Bortezomib results in increased expression of IBTK mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:93,323,454...93,397,044
Ensembl chr 8:93,324,476...93,390,305
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of ICAM1 mRNA; [romidepsin co-treated with Bortezomib] results in decreased expression of ICAM1 protein Bortezomib results in decreased expression of ICAM1 mRNA |
CTD |
PMID:18223231 PMID:20471514 PMID:25913414 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Ide |
insulin degrading enzyme |
increases expression |
ISO |
Bortezomib results in increased expression of IDE mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:255,914,465...256,014,168
Ensembl chr 1:255,914,447...256,013,495
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of IDH3A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr 8:59,164,601...59,183,899
Ensembl chr 8:59,164,572...59,183,908
|
|
G |
Ifi44 |
interferon-induced protein 44 |
increases expression |
ISO |
Bortezomib results in increased expression of IFI44 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:256,897,765...256,915,591
Ensembl chr 2:256,897,772...256,915,569
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]] |
CTD |
PMID:30482226 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ifrd2 |
interferon-related developmental regulator 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of IFRD2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:116,343,096...116,348,318
Ensembl chr 8:116,343,096...116,348,314
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
increases response to substance |
ISO |
IGF1R gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
|
|
G |
Igf2 |
insulin-like growth factor 2 |
multiple interactions decreases response to substance |
ISO |
Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein] Bortezomib results in decreased susceptibility to IGF2 protein |
CTD |
PMID:24055520 |
|
NCBI chr 1:215,828,102...215,839,081
Ensembl chr 1:215,828,102...215,846,911
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions decreases expression |
ISO |
Bortezomib promotes the reaction [abexinostat results in decreased expression of IKBKB mRNA]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein] Bortezomib results in decreased expression of IKBKB mRNA |
CTD |
PMID:19417023 PMID:20471514 PMID:24085292 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Ikzf1 |
IKAROS family zinc finger 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of IKZF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:91,782,281...91,867,828
Ensembl chr14:91,782,354...91,867,424
|
|
G |
Il10 |
interleukin 10 |
affects expression |
ISO |
Bortezomib affects the expression of IL10 protein |
CTD |
PMID:19922463 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il15 |
interleukin 15 |
increases expression |
ISO |
Bortezomib results in increased expression of IL15 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:23,542,606...23,624,366
Ensembl chr19:23,542,889...23,554,594
|
|
G |
Il18r1 |
interleukin 18 receptor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of IL18R1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 9:47,184,404...47,217,403
Ensembl chr 9:47,185,443...47,219,175
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
increases expression |
ISO |
Bortezomib results in increased expression of IL1R1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
|
|
G |
Il23a |
interleukin 23 subunit alpha |
increases expression |
ISO |
Bortezomib results in increased expression of IL23A mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression decreases expression decreases secretion |
ISO |
[Dexamethasone co-treated with Bortezomib] inhibits the reaction [IL6 protein results in increased expression of SOD2 mRNA]; [Dexamethasone co-treated with Bortezomib] results in decreased expression of IL6 mRNA; [Dexamethasone co-treated with Bortezomib] results in decreased secretion of IL6 protein; Bortezomib inhibits the reaction [IL6 protein results in decreased susceptibility to Dexamethasone] Bortezomib inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; Bortezomib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein] Bortezomib results in increased expression of IL6 mRNA Bortezomib results in decreased expression of IL6 mRNA Bortezomib results in decreased secretion of IL6 protein |
CTD |
PMID:17895889 PMID:23063726 PMID:28134560 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of IL7R mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA |
CTD |
PMID:20471514 PMID:25522274 |
|
|
|
G |
Ino80b |
INO80 complex subunit B |
decreases expression |
ISO |
Bortezomib results in decreased expression of INO80B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:113,954,612...113,957,774
Ensembl chr 4:113,954,613...113,957,774
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of IRAK1 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr X:156,716,469...156,726,367
Ensembl chr X:156,716,604...156,725,977
|
|
G |
Irak2 |
interleukin-1 receptor-associated kinase 2 |
increases expression |
ISO |
Bortezomib results in increased expression of IRAK2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:145,594,575...145,651,066
Ensembl chr 4:145,594,575...145,651,053
|
|
G |
Irs1 |
insulin receptor substrate 1 |
decreases degradation |
ISO |
Bortezomib results in decreased degradation of IRS1 protein |
CTD |
PMID:16227402 |
|
NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
|
|
G |
Isca1 |
iron-sulfur cluster assembly 1 |
increases expression |
ISO |
Bortezomib results in increased expression of ISCA1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:5,281,727...5,294,386
Ensembl chr17:5,281,727...5,294,384
|
|
G |
Itga6 |
integrin subunit alpha 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ITGA6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:58,442,904...58,515,124
Ensembl chr 3:58,443,101...58,515,124
|
|
G |
Itgal |
integrin subunit alpha L |
decreases expression |
ISO |
Bortezomib results in decreased expression of ITGAL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:198,744,053...198,781,745
Ensembl chr 1:198,744,050...198,781,750
|
|
G |
Itgav |
integrin subunit alpha V |
multiple interactions increases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of ITGAV mRNA Bortezomib results in increased expression of ITGAV mRNA |
CTD |
PMID:20471514 PMID:25913414 |
|
NCBI chr 3:71,113,269...71,205,958
Ensembl chr 3:71,114,100...71,202,411
|
|
G |
Itgb6 |
integrin subunit beta 6 |
increases expression |
ISO |
Bortezomib results in increased expression of ITGB6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:46,652,624...46,775,362
Ensembl chr 3:46,652,623...46,726,958
|
|
G |
Jak1 |
Janus kinase 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of JAK1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:119,982,503...120,091,452
Ensembl chr 5:119,982,943...120,083,904
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression increases expression increases phosphorylation multiple interactions |
ISO EXP |
Bortezomib results in decreased expression of JUN mRNA Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein; Bortezomib results in increased expression of JUN protein modified form Bortezomib results in increased phosphorylation of JUN protein [arsenic trioxide co-treated with Bortezomib] results in decreased expression of JUN mRNA; [arsenic trioxide co-treated with Bortezomib] results in increased activity of JUN protein modified form; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of JUN protein] |
CTD |
PMID:12393500 PMID:16357177 PMID:16985072 PMID:17351739 PMID:17495969 PMID:17898295 PMID:20471514 PMID:20830808 PMID:25913414 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Bortezomib results in decreased expression of JUND mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:20,485,028...20,486,707
Ensembl chr16:20,485,029...20,486,707
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
decreases expression |
ISO |
Bortezomib results in decreased expression of KAT2B mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 9:4,440,982...4,492,949
|
|
G |
Kat6b |
lysine acetyltransferase 6B |
decreases expression |
ISO |
Bortezomib results in decreased expression of KAT6B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:2,811,933...2,966,833
Ensembl chr15:2,813,537...2,966,576
|
|
G |
Katnal1 |
katanin catalytic subunit A1 like 1 |
increases expression |
ISO |
Bortezomib results in increased expression of KATNAL1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:7,495,436...7,550,205
Ensembl chr12:7,208,850...7,271,872 Ensembl chr12:7,208,850...7,271,872
|
|
G |
Kcmf1 |
potassium channel modulatory factor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of KCMF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:100,759,526...100,783,017
Ensembl chr 4:100,759,526...100,783,750
|
|
G |
Kctd10 |
potassium channel tetramerization domain containing 10 |
increases expression |
ISO |
Bortezomib results in increased expression of KCTD10 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:47,992,079...48,010,531
Ensembl chr12:47,992,091...48,010,583
|
|
G |
Kdelr1 |
KDEL endoplasmic reticulum protein retention receptor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KDELR1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:101,859,346...101,870,232
Ensembl chr 1:101,859,346...101,870,232
|
|
G |
Kdm4b |
lysine demethylase 4B |
decreases expression |
ISO |
Bortezomib results in decreased expression of KDM4B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:10,656,035...10,734,127
Ensembl chr 9:10,653,216...10,734,073
|
|
G |
Kdm5c |
lysine demethylase 5C |
decreases expression |
ISO |
Bortezomib results in decreased expression of KDM5C mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:22,302,664...22,349,298
Ensembl chr X:22,302,485...22,348,627
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
ISO |
[Bortezomib co-treated with sorafenib] results in decreased phosphorylation of KDR protein |
CTD |
PMID:16985072 |
|
NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
|
|
G |
Kif22 |
kinesin family member 22 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KIF22 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:198,461,406...198,476,430
Ensembl chr 1:198,461,169...198,476,476
|
|
G |
Kif9 |
kinesin family member 9 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KIF9 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:118,737,739...118,795,190
Ensembl chr 8:118,744,229...118,794,992
|
|
G |
Kifc1 |
kinesin family member C1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KIFC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:5,509,059...5,526,175
Ensembl chr20:5,509,059...5,526,175
|
|
G |
Klf6 |
Kruppel-like factor 6 |
increases expression |
ISO |
Bortezomib results in increased expression of KLF6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
|
|
G |
Klhdc7b |
kelch domain containing 7B |
increases expression |
ISO |
Bortezomib results in increased expression of KLHDC7B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:130,357,589...130,359,529
Ensembl chr 7:130,357,643...130,359,448
|
|
G |
Klhl20 |
kelch-like family member 20 |
increases expression |
ISO |
Bortezomib results in increased expression of KLHL20 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:78,912,361...78,957,226
Ensembl chr13:78,912,361...78,957,212
|
|
G |
Klrk1 |
killer cell lectin like receptor K1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KLRK1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:163,392,652...163,403,735
Ensembl chr 4:163,393,217...163,403,653
|
|
G |
Kmt2a |
lysine methyltransferase 2A |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of KMT2A mRNA |
CTD |
PMID:25913414 |
|
NCBI chr 8:49,110,407...49,185,872
Ensembl chr 8:49,114,990...49,158,971
|
|
G |
Kpna2 |
karyopherin subunit alpha 2 |
increases expression |
ISO |
Bortezomib results in increased expression of KPNA2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:95,200,029...95,212,111
Ensembl chr10:95,200,030...95,212,111
|
|
G |
Kri1 |
KRI1 homolog |
increases expression |
ISO |
Bortezomib results in increased expression of KRI1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:22,301,025...22,317,049
Ensembl chr 8:22,301,498...22,315,339
|
|
G |
Krit1 |
KRIT1, ankyrin repeat containing |
increases expression |
ISO |
Bortezomib results in increased expression of KRIT1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:27,438,609...27,473,150
Ensembl chr 4:27,438,609...27,473,150
|
|
G |
Ktn1 |
kinectin 1 |
increases expression |
ISO |
Bortezomib results in increased expression of KTN1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:24,465,761...24,552,833
Ensembl chr15:24,479,761...24,553,197
|
|
G |
Lgals2 |
galectin 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of LGALS2 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 7:120,071,122...120,077,612
Ensembl chr 7:120,071,124...120,077,612
|
|
G |
Lgals8 |
galectin 8 |
increases expression |
ISO |
Bortezomib results in increased expression of LGALS8 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:66,487,451...66,515,316
Ensembl chr17:66,487,457...66,511,870
|
|
G |
Lgr4 |
leucine-rich repeat-containing G protein-coupled receptor 4 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 3:101,051,960...101,152,119
Ensembl chr 3:101,051,955...101,152,119
|
|
G |
Lig4 |
DNA ligase 4 |
increases expression |
ISO |
Bortezomib results in increased expression of LIG4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:85,331,771...85,339,496
Ensembl chr16:85,331,866...85,337,769
|
|
G |
Lima1 |
LIM domain and actin binding 1 |
increases expression |
ISO |
Bortezomib results in increased expression of LIMA1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:141,428,113...141,528,447
Ensembl chr 7:141,428,063...141,528,397
|
|
G |
Limd1 |
LIM domains containing 1 |
increases expression |
ISO |
Bortezomib results in increased expression of LIMD1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:132,553,218...132,598,826
Ensembl chr 8:132,553,218...132,598,812
|
|
G |
Lims1 |
LIM zinc finger domain containing 1 |
increases expression |
ISO |
Bortezomib results in increased expression of LIMS1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:27,895,981...28,004,767
Ensembl chr20:27,954,433...28,002,082
|
|
G |
Lmna |
lamin A/C |
increases cleavage |
ISO |
Bortezomib results in increased cleavage of LMNA protein |
CTD |
PMID:20110775 |
|
NCBI chr 2:187,842,884...187,863,552
Ensembl chr 2:187,842,885...187,863,516
|
|
G |
LOC100909954 |
uncharacterized LOC100909954 |
decreases expression |
ISO |
Bortezomib results in decreased expression of C14ORF132 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:129,259,581...129,322,113
|
|
G |
LOC100911664 |
uncharacterized LOC100911664 |
increases expression |
ISO |
Bortezomib results in increased expression of C6ORF62 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:42,256,971...42,268,607
Ensembl chr17:42,257,019...42,276,797
|
|
G |
LOC361985 |
similar to NICE-3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of C1ORF43 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:189,400,696...189,413,614
Ensembl chr 2:189,400,696...189,413,608
|
|
G |
LOC686035 |
similar to heat shock 70kDa protein 6 (HSP70B) |
increases expression |
ISO |
Bortezomib results in increased expression of HSPA6 mRNA |
CTD |
PMID:15509775 PMID:17898295 PMID:20977926 |
|
NCBI chr13:89,408,703...89,411,500
|
|
G |
LOC691807 |
hypothetical protein LOC691807 |
decreases expression |
ISO |
Bortezomib results in decreased expression of C4ORF3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:227,095,487...227,097,247
Ensembl chr 2:227,095,487...227,097,246
|
|
G |
Lrfn4 |
leucine rich repeat and fibronectin type III domain containing 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of LRFN4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:219,850,037...219,855,771
Ensembl chr 1:219,850,037...219,853,329
|
|
G |
Lrrc41 |
leucine rich repeat containing 41 |
decreases expression |
ISO |
Bortezomib results in decreased expression of LRRC41 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:134,927,609...134,948,530
Ensembl chr 5:134,927,609...134,948,529
|
|
G |
Lrrfip1 |
LRR binding FLII interacting protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of LRRFIP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:98,139,484...98,268,148
Ensembl chr 9:98,190,829...98,257,735
|
|
G |
Lsm4 |
LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated |
decreases expression |
ISO |
Bortezomib results in decreased expression of LSM4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:20,506,399...20,511,818
Ensembl chr16:20,506,399...20,511,818
|
|
G |
Lst1 |
leukocyte specific transcript 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of LST1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:5,175,213...5,179,352
Ensembl chr20:5,176,016...5,179,263
|
|
G |
Luc7l |
LUC7-like |
increases expression |
ISO |
Bortezomib results in increased expression of LUC7L mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:15,538,878...15,572,651
Ensembl chr10:15,538,872...15,568,638
|
|
G |
Ly96 |
lymphocyte antigen 96 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in increased expression of LY96 mRNA |
CTD |
PMID:25913414 |
|
NCBI chr 5:1,972,212...1,989,448
|
|
G |
Lyn |
LYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein |
CTD |
PMID:15039284 |
|
NCBI chr 5:16,526,058...16,642,648
Ensembl chr 5:16,526,058...16,642,648
|
|
G |
Maf1 |
MAF1 homolog, negative regulator of RNA polymerase III |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr 7:117,417,643...117,420,722
Ensembl chr 7:117,417,687...117,420,719
|
|
G |
Mafg |
MAF bZIP transcription factor G |
increases expression |
ISO |
Bortezomib results in increased expression of MAFG mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:109,802,877...109,811,476
Ensembl chr10:109,806,159...109,811,323
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:24085292 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
ISO |
[Bortezomib co-treated with Butyrates] results in decreased expression of MAP2K1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein |
CTD |
PMID:12893773 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAP2K2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
|
|
G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
multiple interactions |
ISO |
alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein |
CTD |
PMID:15039284 |
|
NCBI chr10:52,196,121...52,301,887
Ensembl chr10:52,196,124...52,290,657
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAP2K6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:98,707,160...98,823,054
Ensembl chr10:98,706,960...98,823,287
|
|
G |
Map4k3 |
mitogen-activated protein kinase kinase kinase kinase 3 |
increases expression |
ISO |
Bortezomib results in increased expression of MAP4K3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:3,276,732...3,444,519
Ensembl chr 6:3,276,738...3,444,519
|
|
G |
Map4k4 |
mitogen-activated protein kinase kinase kinase kinase 4 |
increases expression |
ISO |
Bortezomib results in increased expression of MAP4K4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:46,657,444...46,782,545
Ensembl chr 9:46,657,575...46,782,545
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases expression increases phosphorylation decreases activity |
ISO |
[Bortezomib co-treated with Butyrates] results in decreased expression of MAPK1 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK1 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK1 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein] Bortezomib results in decreased activity of MAPK1 protein |
CTD |
PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk10 |
mitogen activated protein kinase 10 |
multiple interactions |
ISO |
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein] |
CTD |
PMID:15173093 |
|
NCBI chr14:8,079,955...8,371,508
Ensembl chr14:8,080,275...8,368,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
[Bortezomib co-treated with Butyrates] results in increased phosphorylation of MAPK14 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein] |
CTD |
PMID:12893773 PMID:18790767 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases expression increases phosphorylation decreases activity |
ISO |
[Bortezomib co-treated with Butyrates] results in decreased expression of MAPK3 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK3 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK3 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein] Bortezomib results in decreased activity of MAPK3 protein |
CTD |
PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK8 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein]; MAPK8 results in increased susceptibility to [Bortezomib co-treated with CGC 11093] |
CTD |
PMID:12893773 PMID:15039284 PMID:15173093 PMID:16985072 PMID:18559525 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation multiple interactions |
ISO |
Bortezomib results in increased phosphorylation of MAPK9 protein [Bortezomib co-treated with arsenic trioxide] affects the expression of MAPK9 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK9 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK9 protein]; MAPK9 results in increased susceptibility to [Bortezomib co-treated with CGC 11093] |
CTD |
PMID:16985072 PMID:18559525 PMID:18718063 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mapkap1 |
MAPK associated protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAPKAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:13,484,952...13,701,772
Ensembl chr 3:13,484,838...13,701,757
|
|
G |
Mapkapk2 |
MAPK activated protein kinase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAPKAPK2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:47,785,157...47,871,684
Ensembl chr13:47,785,161...47,831,110
|
|
G |
Mark2 |
microtubule affinity regulating kinase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MARK2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:222,525,547...222,590,727
Ensembl chr 1:222,525,990...222,590,220
|
|
G |
Maz |
MYC associated zinc finger protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAZ mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:198,456,699...198,460,126
Ensembl chr 1:198,456,699...198,460,126
|
|
G |
Mbd1 |
methyl-CpG binding domain protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MBD1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:70,248,568...70,263,190
Ensembl chr18:70,248,713...70,263,164
|
|
G |
Mbd4 |
methyl-CpG binding domain 4 DNA glycosylase |
increases expression |
ISO |
Bortezomib results in increased expression of MBD4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:147,744,673...147,756,462
Ensembl chr 4:147,746,186...147,756,294
|
|
G |
Mbl2 |
mannose binding lectin 2 |
increases response to substance |
ISO |
MBL2 gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr 1:248,435,069...248,442,669
Ensembl chr 1:248,723,397...248,729,962
|
|
G |
Mbnl1 |
muscleblind-like splicing regulator 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MBNL1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:150,698,248...150,867,791
Ensembl chr 2:150,756,185...150,869,690
|
|
G |
Mbp |
myelin basic protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of MBP mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:79,326,738...79,437,310
Ensembl chr18:79,326,738...79,437,310
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions increases expression decreases response to substance increases cleavage |
ISO |
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein modified form; [Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; romidepsin inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of MCL1 protein]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of MCL1 protein] Bortezomib inhibits the reaction [Acetaminophen results in decreased expression of MCL1 protein] MCL1 protein results in decreased susceptibility to Bortezomib; MCL1 results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of MCL1; Bortezomib results in increased expression of MCL1 protein |
CTD |
PMID:12893773 PMID:15173093 PMID:16617327 PMID:18223231 PMID:18534018 PMID:18566236 PMID:18625202 PMID:19100720 PMID:20051518 PMID:21195056 PMID:21345073 PMID:25752611 PMID:26769846 |
|
NCBI chr 2:197,786,212...197,788,992
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MCM7 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr12:19,306,615...19,313,877
Ensembl chr12:19,306,607...19,314,016
|
|
G |
Mdc1 |
mediator of DNA damage checkpoint 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MDC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:3,405,017...3,419,831
Ensembl chr20:3,404,711...3,419,831
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions increases cleavage affects expression |
ISO |
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein] Bortezomib affects the expression of MDM2 protein |
CTD |
PMID:12393500 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Me1 |
malic enzyme 1 |
increases expression |
ISO |
Bortezomib results in increased expression of ME1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:94,256,830...94,368,834
Ensembl chr 8:94,256,839...94,368,834
|
|
G |
Mettl21a |
methyltransferase like 21A |
increases expression |
ISO |
Bortezomib results in increased expression of METTL21A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:71,304,138...71,314,015
Ensembl chr 9:71,304,427...71,313,940
|
|
G |
Mettl27 |
methyltransferase like 27 |
decreases expression |
ISO |
Bortezomib results in decreased expression of METTL27 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:24,767,351...24,775,891
Ensembl chr12:24,767,351...24,775,891
|
|
G |
Mex3d |
mex-3 RNA binding family member D |
decreases expression |
ISO |
Bortezomib results in decreased expression of MEX3D mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:12,191,902...12,198,841
Ensembl chr 7:12,192,088...12,198,551
|
|
G |
Mfn1 |
mitofusin 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MFN1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:118,929,738...118,971,689
Ensembl chr 2:118,929,738...118,973,698
|
|
G |
Mfng |
MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase |
decreases expression |
ISO |
Bortezomib results in decreased expression of MFNG mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:119,978,981...119,996,824
Ensembl chr 7:119,978,983...119,996,824
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [Disulfiram results in increased degradation of MGMT protein] |
CTD |
PMID:24193513 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Mir21 |
microRNA 21 |
increases expression |
ISO |
Bortezomib results in increased expression of MIR21 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:73,902,210...73,902,301
Ensembl chr10:73,902,210...73,902,301
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of MKI67 protein [Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]] |
CTD |
PMID:19372569 PMID:30482226 |
|
NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
increases expression |
ISO |
Bortezomib results in increased expression of MLLT11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:196,392,936...196,402,106
Ensembl chr 2:196,392,938...196,402,106
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Bortezomib promotes the reaction [butein results in decreased expression of MMP9 protein] |
CTD |
PMID:20696233 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mob3a |
MOB kinase activator 3A |
decreases expression |
ISO |
Bortezomib results in decreased expression of MOB3A mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 7:11,878,943...11,896,226
Ensembl chr 7:11,878,943...11,896,223
|
|
G |
Morc2 |
MORC family CW-type zinc finger 2 |
increases expression |
ISO |
Bortezomib results in increased expression of MORC2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:83,889,138...83,930,263
Ensembl chr14:83,889,089...83,930,522
|
|
G |
Mpz |
myelin protein zero |
decreases expression |
EXP ISO |
Bortezomib results in decreased expression of MPZ mRNA; Bortezomib results in decreased expression of MPZ protein |
CTD |
PMID:20830808 |
|
NCBI chr13:89,524,204...89,530,070
Ensembl chr13:89,524,329...89,530,068
|
|
G |
Mrpl19 |
mitochondrial ribosomal protein L19 |
increases expression |
ISO |
Bortezomib results in increased expression of MRPL19 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:112,703,041...112,707,270
Ensembl chr 4:112,703,041...112,707,270
|
|
G |
Mrpl30 |
mitochondrial ribosomal protein L30 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MRPL30 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:44,483,809...44,496,116
Ensembl chr 9:44,483,875...44,571,331
|
|
G |
Mrps12 |
mitochondrial ribosomal protein S12 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MRPS12 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:86,920,679...86,923,626
Ensembl chr 1:86,920,680...86,923,575
|
|
G |
Mrps5 |
mitochondrial ribosomal protein S5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MRPS5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:120,165,953...120,182,536
Ensembl chr 3:120,165,913...120,182,536
|
|
G |
Msh6 |
mutS homolog 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MSH6 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 6:11,644,565...11,662,389
Ensembl chr 6:11,644,578...11,662,499
|
|
G |
Mtmr6 |
myotubularin related protein 6 |
increases expression |
ISO |
Bortezomib results in increased expression of MTMR6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:40,558,917...40,597,311
Ensembl chr15:40,558,932...40,597,309
|
|
G |
Muc1 |
mucin 1, cell surface associated |
decreases expression |
ISO |
Bortezomib results in decreased expression of MUC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:188,543,137...188,547,874
Ensembl chr 2:188,543,137...188,547,874
|
|
G |
Mutyh |
mutY DNA glycosylase |
decreases expression |
ISO |
Bortezomib results in decreased expression of MUTYH mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 5:135,663,328...135,675,348
Ensembl chr 5:135,663,371...135,675,344
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions increases expression decreases expression |
ISO |
[Bortezomib co-treated with abexinostat] results in decreased expression of MYC mRNA; Bortezomib promotes the reaction [abexinostat results in decreased expression of MYC protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein] Bortezomib results in increased expression of MYC protein Bortezomib results in decreased expression of MYC protein |
CTD |
PMID:12902978 PMID:18641367 PMID:19417023 PMID:20022965 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
decreases expression |
ISO |
Bortezomib results in decreased expression of MYD88 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
|
|
G |
Myl12a |
myosin light chain 12A |
increases expression |
ISO |
Bortezomib results in increased expression of MYL12A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:119,325,282...119,333,012
Ensembl chr 9:119,325,283...119,332,967
|
|
G |
Myo5a |
myosin VA |
increases response to substance |
ISO |
MYO5A gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr 8:82,038,966...82,156,507
Ensembl chr 8:82,037,977...82,156,617
|
|
G |
Naa80 |
N(alpha)-acetyltransferase 80, NatH catalytic subunit |
decreases expression |
ISO |
Bortezomib results in decreased expression of NAA80 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 8:116,336,441...116,339,691
Ensembl chr 8:116,336,441...116,339,690
|
|
G |
Nab2 |
Ngfi-A binding protein 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NAB2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:70,963,580...70,971,471
Ensembl chr 7:70,961,575...70,969,905
|
|
G |
Nabp1 |
nucleic acid binding protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of NABP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:55,049,893...55,057,784
Ensembl chr 9:55,050,203...55,057,658
|
|
G |
Nadk |
NAD kinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of NADK mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:172,984,930...173,015,505
Ensembl chr 5:172,986,291...173,015,494
|
|
G |
Nadk2 |
NAD kinase 2, mitochondrial |
increases expression |
ISO |
Bortezomib results in increased expression of NADK2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:58,462,588...58,504,735
Ensembl chr 2:58,462,588...58,504,728
|
|
G |
Naf1 |
nuclear assembly factor 1 ribonucleoprotein |
increases expression |
ISO |
Bortezomib results in increased expression of NAF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:24,582,000...24,612,773
Ensembl chr16:24,578,678...24,612,732
|
|
G |
Naip6 |
NLR family, apoptosis inhibitory protein 6 |
affects expression |
ISO |
Bortezomib affects the expression of NAIP mRNA |
CTD |
PMID:25913414 |
|
NCBI chr 2:30,377,505...30,418,578
|
|
G |
Nap1l2 |
nucleosome assembly protein 1-like 2 |
increases expression |
ISO |
Bortezomib results in increased expression of NAP1L2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:73,997,274...73,999,677
|
|
G |
Ncf4 |
neutrophil cytosolic factor 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NCF4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:119,481,711...119,499,426
Ensembl chr 7:119,482,272...119,499,425
|
|
G |
Nckap1 |
NCK-associated protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of NCKAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:67,725,180...67,804,680
Ensembl chr 3:67,725,947...67,787,990
|
|
G |
Ncoa3 |
nuclear receptor coactivator 3 |
increases expression |
ISO |
Bortezomib results in increased expression of NCOA3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:162,692,176...162,788,582
Ensembl chr 3:162,692,185...162,787,548
|
|
G |
Ncr1 |
natural cytotoxicity triggering receptor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NCR1 protein |
CTD |
PMID:19229052 |
|
NCBI chr 1:73,178,917...73,226,504
Ensembl chr 1:73,179,013...73,226,777
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
increases expression |
ISO |
Bortezomib results in increased expression of NDRG1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:107,734,326...107,775,701
Ensembl chr 7:107,734,323...107,775,714
|
|
G |
Ndrg3 |
NDRG family member 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NDRG3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:152,972,055...153,099,089
|
|
G |
Nedd1 |
NEDD1 gamma-tubulin ring complex targeting factor |
increases expression |
ISO |
Bortezomib results in increased expression of NEDD1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:33,544,097...33,584,406
Ensembl chr 7:33,543,828...33,584,564
|
|
G |
Neto2 |
neuropilin and tolloid like 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NETO2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:22,450,579...22,486,530
Ensembl chr19:22,450,030...22,486,531
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases expression increases activity |
ISO |
[Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of NFE2L2 protein Bortezomib results in increased activity of NFE2L2 protein |
CTD |
PMID:20806931 PMID:30818834 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfia |
nuclear factor I/A |
decreases expression |
ISO |
Bortezomib results in decreased expression of NFIA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:116,421,895...116,750,381
Ensembl chr 5:116,420,690...116,751,416
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases expression |
ISO |
[Bortezomib co-treated with vorinostat] results in decreased activity of [NFKB1 protein binds to RELA protein]; [resveratrol co-treated with Bortezomib] results in decreased activity of [RELA protein binds to NFKB1 protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKB1 protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKB1 protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]] Bortezomib results in decreased expression of NFKB1 mRNA; Bortezomib results in decreased expression of NFKB1 protein |
CTD |
PMID:12893773 PMID:16230421 PMID:17164350 PMID:17626072 PMID:18223231 PMID:25913414 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
decreases cleavage decreases expression |
ISO |
Bortezomib results in decreased cleavage of NFKB2 protein Bortezomib results in decreased expression of NFKB2 mRNA; Bortezomib results in decreased expression of NFKB2 protein |
CTD |
PMID:17626072 PMID:18223231 PMID:25913414 |
|
NCBI chr 1:266,050,634...266,059,277
Ensembl chr 1:266,053,002...266,059,256
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases phosphorylation increases stability increases degradation increases expression decreases degradation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of NFKBIA protein; [Bortezomib co-treated with TNFSF10 protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; [Dexamethasone co-treated with Bortezomib] results in increased expression of NFKBIA mRNA; [Dexamethasone co-treated with Bortezomib] results in increased phosphorylation of NFKBIA protein; alvocidib promotes the reaction [Bortezomib results in increased expression of NFKBIA protein modified form]; Ammonium Chloride inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKBIA protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKBIA protein]; Bortezomib promotes the reaction [alvocidib results in increased expression of NFKBIA protein modified form]; Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Chloroquine inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Dexamethasone inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; NFKBIA protein mutant form inhibits the reaction [Bortezomib results in increased expression of PTGS2 protein]; SC 514 affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; SC 514 inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein] Bortezomib results in increased stability of NFKBIA protein Bortezomib results in increased expression of NFKBIA mRNA; Bortezomib results in increased expression of NFKBIA protein modified form Bortezomib results in decreased degradation of NFKBIA protein |
CTD |
PMID:15039284 PMID:15543232 PMID:17895889 PMID:18089816 PMID:18223231 PMID:18718063 PMID:19261616 PMID:23063726 PMID:24085292 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nfkbib |
NFKB inhibitor beta |
increases stability increases expression |
ISO |
Bortezomib results in increased stability of NFKBIB protein Bortezomib results in increased expression of NFKBIB mRNA |
CTD |
PMID:15543232 PMID:20977926 PMID:25913414 |
|
NCBI chr 1:86,941,073...86,948,845
Ensembl chr 1:86,941,074...86,948,845
|
|
G |
Nfkbie |
NFKB inhibitor epsilon |
multiple interactions increases stability |
ISO |
Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of NFKBIE mRNA] Bortezomib results in increased stability of NFKBIE protein |
CTD |
PMID:15543232 PMID:20471514 |
|
NCBI chr 9:17,828,405...17,835,240
Ensembl chr 9:17,828,408...17,835,240
|
|
G |
Nfyc |
nuclear transcription factor Y subunit gamma |
decreases expression |
ISO |
Bortezomib results in decreased expression of NFYC mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:139,687,442...139,760,154
Ensembl chr 5:139,687,448...139,749,050
|
|
G |
Nipsnap1 |
nipsnap homolog 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NIPSNAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:85,113,578...85,137,457
Ensembl chr14:85,113,578...85,137,454
|
|
G |
Nlrp12 |
NLR family, pyrin domain containing 12 |
multiple interactions increases expression |
ISO |
Bortezomib promotes the reaction [arsenic trioxide results in increased expression of NLRP12 mRNA] Bortezomib results in increased expression of NLRP12 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 1:64,506,750...64,543,908
Ensembl chr 1:64,506,735...64,534,912
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NLRP3 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
|
|
G |
Nos1 |
nitric oxide synthase 1 |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of NOS1 protein betulinic acid inhibits the reaction [Bortezomib results in increased expression of NOS1 protein] |
CTD |
PMID:30482226 |
|
NCBI chr12:44,214,949...44,405,530
Ensembl chr12:44,213,943...44,520,341
|
|
G |
Notch2 |
notch receptor 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NOTCH2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:200,187,184...200,320,403
Ensembl chr 2:200,187,179...200,320,215
|
|
G |
Npm1 |
nucleophosmin 1 |
multiple interactions affects response to substance increases response to substance |
ISO |
Acetylcysteine inhibits the reaction [NPM1 protein mutant form results in increased susceptibility to Bortezomib] NPM1 protein affects the susceptibility to Bortezomib |
CTD |
PMID:23877794 |
|
NCBI chr10:18,080,949...18,091,062
Ensembl chr10:18,080,950...18,090,950
|
|
G |
Nptx1 |
neuronal pentraxin 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NPTX1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:108,682,637...108,691,592
Ensembl chr10:108,682,638...108,691,367
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
Bortezomib results in increased expression of NQO1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nqo2 |
N-ribosyldihydronicotinamide:quinone reductase 2 |
increases expression |
ISO |
Bortezomib results in increased expression of NQO2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:32,131,847...32,158,559
Ensembl chr17:32,132,347...32,158,538
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NR1H3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein] |
CTD |
PMID:30818834 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Nrip3 |
nuclear receptor interacting protein 3 |
increases expression |
EXP |
Bortezomib results in increased expression of NRIP3 mRNA |
CTD |
PMID:20830808 |
|
NCBI chr 1:174,385,424...174,411,141
Ensembl chr 1:174,385,424...174,411,141
|
|
G |
Nt5c2 |
5'-nucleotidase, cytosolic II |
increases expression |
ISO |
Bortezomib results in increased expression of NT5C2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:266,652,966...266,782,935
Ensembl chr 1:266,659,519...266,782,910
|
|
G |
Nt5e |
5' nucleotidase, ecto |
decreases expression |
ISO |
Bortezomib results in decreased expression of NT5E mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:95,969,002...96,012,733
Ensembl chr 8:95,968,652...96,012,696
|
|
G |
Nub1 |
negative regulator of ubiquitin-like proteins 1 |
increases expression |
ISO |
Bortezomib results in increased expression of NUB1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:6,950,870...6,981,400
Ensembl chr 4:6,951,478...6,978,073
|
|
G |
Nucks1 |
nuclear casein kinase and cyclin-dependent kinase substrate 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NUCKS1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:48,679,726...48,709,663
Ensembl chr13:48,679,774...48,705,575
|
|
G |
Numb |
NUMB, endocytic adaptor protein |
increases expression |
ISO |
Bortezomib results in increased expression of NUMB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:107,279,917...107,325,345
Ensembl chr 6:107,279,920...107,325,345
|
|
G |
Numbl |
NUMB-like, endocytic adaptor protein |
increases expression |
ISO |
Bortezomib results in increased expression of NUMBL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:84,067,841...84,091,659
Ensembl chr 1:84,067,938...84,091,671
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
multiple interactions increases expression |
ISO |
NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA] Bortezomib results in increased expression of NUPR1 mRNA |
CTD |
PMID:20022965 |
|
NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
|
|
G |
Nxpe3 |
neurexophilin and PC-esterase domain family, member 3 |
increases expression |
ISO |
Bortezomib results in increased expression of NXPE3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:47,188,332...47,238,372
Ensembl chr11:47,188,495...47,238,372
|
|
G |
Obscn |
obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF |
decreases expression |
ISO |
Bortezomib results in decreased expression of OBSCN mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:45,353,185...45,483,570
Ensembl chr10:45,338,009...45,481,008
|
|
G |
Ogdh |
oxoglutarate dehydrogenase |
decreases expression |
ISO |
Bortezomib results in decreased expression of OGDH mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:86,414,924...86,481,903
Ensembl chr14:86,414,949...86,613,327
|
|
G |
Ogfr |
opioid growth factor receptor |
decreases expression |
ISO |
Bortezomib results in decreased expression of OGFR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:176,093,662...176,099,949
Ensembl chr 3:175,930,505...176,099,987
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
decreases expression |
ISO |
Bortezomib results in decreased expression of OGT mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:71,540,870...71,585,906
Ensembl chr X:71,528,988...71,585,908
|
|
G |
Orai2 |
ORAI calcium release-activated calcium modulator 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ORAI2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:23,544,483...23,564,602
Ensembl chr12:23,544,287...23,564,569
|
|
G |
Os9 |
OS9, endoplasmic reticulum lectin |
increases expression |
ISO |
Bortezomib results in increased expression of OS9 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:70,378,625...70,407,135
Ensembl chr 7:70,380,311...70,407,177
|
|
G |
Osbpl2 |
oxysterol binding protein-like 2 |
increases expression |
ISO |
Bortezomib results in increased expression of OSBPL2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:175,493,650...175,538,965
Ensembl chr 3:175,493,698...175,538,963
|
|
G |
Osgin1 |
oxidative stress induced growth inhibitor 1 |
increases expression |
ISO EXP |
Bortezomib results in increased expression of OSGIN1 mRNA |
CTD |
PMID:20830808 PMID:20977926 |
|
NCBI chr19:52,056,808...52,085,491
Ensembl chr19:52,077,109...52,085,496
|
|
G |
Pacsin1 |
protein kinase C and casein kinase substrate in neurons 1 |
increases expression |
ISO |
Bortezomib results in increased expression of PACSIN1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:7,241,248...7,286,702
Ensembl chr20:7,279,820...7,286,586
|
|
G |
Palld |
palladin, cytoskeletal associated protein |
increases expression |
ISO |
Bortezomib results in increased expression of PALLD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:31,865,712...31,948,168
|
|
G |
Panx2 |
pannexin 2 |
increases expression |
ISO |
Bortezomib results in increased expression of PANX2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:130,042,948...130,053,034
Ensembl chr 7:130,042,947...130,053,032
|
|
G |
Papola |
poly (A) polymerase alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of PAPOLA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:129,609,068...129,662,002
Ensembl chr 6:129,609,074...129,661,531
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage increases expression |
ISO |
[alvocidib co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [arsenic trioxide co-treated with Bortezomib] results in increased degradation of PARP1 protein; [Bortezomib co-treated with abexinostat] results in increased activity of PARP1 protein; [Bortezomib co-treated with Butyrates] results in increased degradation of PARP1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of PARP1 protein; [Bortezomib co-treated with vorinostat] results in increased degradation of PARP1 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [Curcumin co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [Dichlororibofuranosylbenzimidazole co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [RB1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]]; Bortezomib promotes the reaction [belinostat results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; Bortezomib results in increased cleavage of and results in increased activity of PARP1 protein; gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein] Bortezomib results in increased expression of PARP1 protein |
CTD |
PMID:12893773 PMID:12902978 PMID:15039284 PMID:16617327 PMID:16904634 PMID:16985072 PMID:17156654 PMID:17326159 PMID:17495969 PMID:17510429 PMID:17659339 PMID:17898295 PMID:17898787 PMID:18223231 PMID:18723477 PMID:18790767 PMID:19261616 PMID:19372569 PMID:19417023 PMID:20110775 PMID:20383943 PMID:20461078 PMID:21195056 PMID:24291039 PMID:25522274 PMID:29384525 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Parp6 |
poly (ADP-ribose) polymerase family, member 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PARP6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:64,439,933...64,472,443
Ensembl chr 8:64,440,214...64,472,443
|
|
G |
Patz1 |
POZ (BTB) and AT hook containing zinc finger 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PATZ1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:83,509,763...83,528,898
Ensembl chr14:83,510,278...83,528,898
|
|
G |
Pawr |
pro-apoptotic WT1 regulator |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 7:51,273,764...51,353,700
Ensembl chr 7:51,273,771...51,353,068
|
|
G |
Pbx3 |
PBX homeobox 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PBX3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:13,241,031...13,436,084
Ensembl chr 3:13,182,024...13,525,983
|
|
G |
Pcgf3 |
polycomb group ring finger 3 |
increases expression |
ISO |
Bortezomib results in increased expression of PCGF3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:2,247,805...2,297,155
Ensembl chr14:2,247,808...2,297,155
|
|
G |
Pcnx4 |
pecanex 4 |
increases expression |
ISO |
Bortezomib results in increased expression of PCNX4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:95,314,867...95,452,631
|
|
G |
Pcyt1a |
phosphate cytidylyltransferase 1, choline, alpha |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of PCYT1A mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA |
CTD |
PMID:20977926 PMID:25522274 |
|
NCBI chr11:71,547,865...71,592,037
Ensembl chr11:71,548,222...71,591,502
|
|
G |
Pdcl |
phosducin-like |
increases expression |
ISO |
Bortezomib results in increased expression of PDCL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:21,602,349...21,609,821
Ensembl chr 3:21,601,816...21,609,853
|
|
G |
Pde7a |
phosphodiesterase 7A |
decreases expression |
ISO |
Bortezomib results in decreased expression of PDE7A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:104,042,124...104,134,101
Ensembl chr 2:104,045,811...104,134,101
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
ISO |
[Bortezomib co-treated with sorafenib] results in decreased phosphorylation of PDGFRB protein |
CTD |
PMID:16985072 |
|
NCBI chr18:56,364,586...56,406,381
Ensembl chr18:56,364,620...56,406,381
|
|
G |
Pdk2 |
pyruvate dehydrogenase kinase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PDK2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:82,838,270...82,852,758
Ensembl chr10:82,839,153...82,852,660
|
|
G |
Pfdn4 |
prefoldin subunit 4 |
increases expression |
ISO |
Bortezomib results in increased expression of PFDN4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:168,124,634...168,132,739
Ensembl chr 3:168,124,673...168,132,786
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Bortezomib binds to and results in decreased activity of PGR protein; Bortezomib inhibits the reaction [Promegestone results in increased activity of PGR protein] |
CTD |
PMID:25752796 PMID:30818834 |
|
NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
|
|
G |
Phc3 |
polyhomeotic homolog 3 |
increases expression |
ISO |
Bortezomib results in increased expression of PHC3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:116,028,735...116,103,227
Ensembl chr 2:116,028,781...116,096,045
|
|
G |
Phf1 |
PHD finger protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of PHF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:5,526,926...5,531,940
Ensembl chr20:5,526,961...5,531,941
|
|
G |
Phkb |
phosphorylase kinase regulatory subunit beta |
increases expression |
ISO |
Bortezomib results in increased expression of PHKB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:22,031,684...22,281,788
Ensembl chr19:22,033,228...22,281,778
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
increases expression |
ISO |
Bortezomib results in increased expression of PHLDA1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:54,247,460...54,249,664
Ensembl chr 7:54,247,460...54,249,664
|
|
G |
Phtf1 |
putative homeodomain transcription factor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of PHTF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:206,452,115...206,518,387
Ensembl chr 2:206,454,208...206,493,030
|
|
G |
Pi4kb |
phosphatidylinositol 4-kinase beta |
decreases expression |
ISO |
Bortezomib results in decreased expression of PI4KB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:196,139,724...196,172,055
Ensembl chr 2:196,139,755...196,171,713
|
|
G |
Pip4p1 |
phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PIP4P1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:27,852,152...27,855,999
Ensembl chr15:27,852,154...27,855,999
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of PIP5K1A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:196,227,669...196,270,949
Ensembl chr 2:196,227,670...196,270,826
|
|
G |
Pir |
pirin |
increases expression |
ISO |
Bortezomib results in increased expression of PIR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:31,852,322...31,968,152
Ensembl chr X:31,852,323...31,968,152
|
|
G |
Pkia |
cAMP-dependent protein kinase inhibitor alpha |
increases expression |
ISO |
Bortezomib results in increased expression of PKIA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:96,593,185...96,668,222
Ensembl chr 2:96,595,088...96,668,222
|
|
G |
Plaa |
phospholipase A2, activating protein |
increases expression |
ISO |
Bortezomib results in increased expression of PLAA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:113,548,913...113,578,928
Ensembl chr 5:113,548,913...113,578,928
|
|
G |
Plekhm2 |
pleckstrin homology and RUN domain containing M2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PLEKHM2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:160,182,556...160,219,770
Ensembl chr 5:160,182,251...160,219,812
|
|
G |
Pm20d2 |
peptidase M20 domain containing 2 |
increases expression |
ISO |
Bortezomib results in increased expression of PM20D2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:48,416,005...48,437,054
Ensembl chr 5:48,420,302...48,436,531
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions increases response to substance increases expression decreases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of PMAIP1 mRNA; [Bortezomib co-treated with arsenic trioxide] results in increased expression of PMAIP1 protein; [Bortezomib co-treated with vorinostat] results in increased expression of PMAIP1 protein; [nutlin 3 co-treated with Bortezomib] results in increased expression of PMAIP1 protein; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with arsenic trioxide] results in increased activity of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein] PMAIP1 protein results in increased susceptibility to Bortezomib; PMAIP1 results in increased susceptibility to Bortezomib Bortezomib results in increased expression of PMAIP1 mRNA; Bortezomib results in increased expression of PMAIP1 protein Bortezomib results in decreased expression of PMAIP1 mRNA |
CTD |
PMID:16024631 PMID:16166592 PMID:16928686 PMID:17898295 PMID:18534018 PMID:18641367 PMID:18790767 PMID:20022965 PMID:20051518 PMID:20850924 PMID:20977926 PMID:21518486 PMID:25913414 |
|
NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
|
|
G |
Pnisr |
PNN interacting serine and arginine rich protein |
increases expression |
ISO |
Bortezomib results in increased expression of PNISR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:35,991,028...36,017,952
Ensembl chr 5:35,991,068...36,017,944
|
|
G |
Pnmt |
phenylethanolamine-N-methyltransferase |
decreases expression |
ISO |
Bortezomib results in decreased expression of PNMT mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:86,340,893...86,342,501
Ensembl chr10:86,340,940...86,342,858
|
|
G |
Pno1 |
partner of NOB1 homolog |
increases expression |
ISO |
Bortezomib results in increased expression of PNO1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:100,364,192...100,372,760
Ensembl chr14:100,364,190...100,372,760
|
|
G |
Poc1b |
POC1 centriolar protein B |
increases expression |
ISO |
Bortezomib results in increased expression of POC1B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:41,304,119...41,404,360
Ensembl chr 7:41,304,440...41,404,370
|
|
G |
Polm |
DNA polymerase mu |
decreases expression |
ISO |
Bortezomib results in decreased expression of POLM mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:86,069,378...86,079,327
Ensembl chr14:86,069,016...86,078,954
|
|
G |
Polr2a |
RNA polymerase II subunit A |
multiple interactions |
ISO |
Bortezomib promotes the reaction [alvocidib results in decreased phosphorylation of POLR2A protein]; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased phosphorylation of POLR2A protein] |
CTD |
PMID:15039284 |
|
NCBI chr10:56,339,277...56,364,888
Ensembl chr10:56,339,284...56,365,084
|
|
G |
Polr3e |
RNA polymerase III subunit E |
increases expression |
ISO |
Bortezomib results in increased expression of POLR3E mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:190,852,954...190,881,539
Ensembl chr 1:190,852,985...190,881,108
|
|
G |
Polr3h |
RNA polymerase III subunit H |
decreases expression |
ISO |
Bortezomib results in decreased expression of POLR3H mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:123,146,248...123,156,558
Ensembl chr 7:123,146,249...123,156,558
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases response to substance |
ISO |
PPARD gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Ppm1a |
protein phosphatase, Mg2+/Mn2+ dependent, 1A |
increases expression |
ISO |
Bortezomib results in increased expression of PPM1A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:94,433,658...94,484,979
Ensembl chr 6:94,429,068...94,484,351
|
|
G |
Ppm1f |
protein phosphatase, Mg2+/Mn2+ dependent, 1F |
increases expression |
ISO |
Bortezomib results in increased expression of PPM1F mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:88,313,709...88,343,726
Ensembl chr11:88,313,709...88,343,627
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression |
ISO |
Bortezomib results in increased expression of PPP1R15A mRNA; Bortezomib results in increased expression of PPP1R15A protein |
CTD |
PMID:15509775 PMID:20022965 |
|
NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
|
|
G |
Ppp2r2a |
protein phosphatase 2, regulatory subunit B, alpha |
increases expression |
ISO |
Bortezomib results in increased expression of PPP2R2A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:43,673,958...43,733,182
Ensembl chr15:43,673,960...43,733,182
|
|
G |
Ppp2r5d |
protein phosphatase 2, regulatory subunit B', delta |
decreases expression |
ISO |
Bortezomib results in decreased expression of PPP2R5D mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:16,580,995...16,610,425
Ensembl chr 9:16,586,803...16,609,631
|
|
G |
Ppp3r1 |
protein phosphatase 3, regulatory subunit B, alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of PPP3R1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:100,311,224...100,360,879
Ensembl chr14:100,311,173...100,360,879
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
decreases expression |
ISO |
Bortezomib results in decreased expression of PPP5C mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:78,944,054...78,968,361
Ensembl chr 1:78,944,040...78,968,329
|
|
G |
Prdm2 |
PR/SET domain 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PRDM2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:161,769,587...161,879,150
Ensembl chr 5:161,770,653...161,879,133
|
|
G |
Prf1 |
perforin 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PRF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:30,915,294...30,920,804
Ensembl chr20:30,915,213...30,921,382
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in increased cleavage of and results in increased activity of PRKCD protein; Bortezomib promotes the reaction [NSC606985 results in increased activity of and results in increased cleavage of PRKCD protein] |
CTD |
PMID:17495969 PMID:19662097 |
|
NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
|
|
G |
Prkdc |
protein kinase, DNA-activated, catalytic subunit |
multiple interactions increases cleavage decreases expression |
ISO |
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of PRKDC protein] Bortezomib results in decreased expression of PRKDC mRNA |
CTD |
PMID:12393500 PMID:20977926 |
|
NCBI chr11:89,293,547...89,510,948
Ensembl chr11:89,293,696...89,510,871
|
|
G |
Prnp |
prion protein |
increases expression |
ISO |
Bortezomib results in increased expression of PRNP mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:124,515,917...124,531,320
Ensembl chr 3:124,515,978...124,531,316
|
|
G |
Prpf6 |
pre-mRNA processing factor 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PRPF6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:177,098,137...177,162,937
Ensembl chr 3:177,098,073...177,162,916
|
|
G |
Prr7 |
proline rich 7 (synaptic) |
decreases expression |
ISO |
Bortezomib results in decreased expression of PRR7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:9,693,274...9,702,795
Ensembl chr17:9,694,168...9,695,292
|
|
G |
Psap |
prosaposin |
increases expression |
ISO |
Bortezomib results in increased expression of PSAP mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:29,831,302...29,856,876
Ensembl chr20:29,831,314...29,856,875
|
|
G |
Psen1 |
presenilin 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PSEN1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:107,169,514...107,221,000
Ensembl chr 6:107,169,528...107,216,798
|
|
G |
Psmb5 |
proteasome 20S subunit beta 5 |
affects binding affects response to substance increases expression decreases response to substance |
ISO EXP |
Bortezomib binds to PSMB5 protein PSMB5 protein affects the susceptibility to Bortezomib Bortezomib results in increased expression of PSMB5 mRNA PSMB5 gene mutant form results in decreased susceptibility to Bortezomib |
CTD |
PMID:20213465 PMID:22216088 |
|
NCBI chr15:33,259,039...33,263,634
Ensembl chr15:33,259,043...33,263,659
|
|
G |
Psmc4 |
proteasome 26S subunit, ATPase 4 |
increases expression |
ISO |
Bortezomib results in increased expression of PSMC4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:84,978,220...84,986,536
Ensembl chr 1:84,978,206...84,986,581
|
|
G |
Psmd12 |
proteasome 26S subunit, non-ATPase 12 |
increases expression |
ISO |
Bortezomib results in increased expression of PSMD12 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:95,706,808...95,725,452
Ensembl chr10:95,706,685...95,725,812
|
|
G |
Psmd13 |
proteasome 26S subunit, non-ATPase 13 |
increases expression |
ISO |
Bortezomib results in increased expression of PSMD13 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:213,636,159...213,648,499
Ensembl chr 1:213,636,093...213,648,488
|
|
G |
Psmd7 |
proteasome 26S subunit, non-ATPase 7 |
increases expression |
ISO |
Bortezomib results in increased expression of PSMD7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:39,639,432...39,646,718
Ensembl chr19:39,639,431...39,646,693
|
|
G |
Psmf1 |
proteasome inhibitor subunit 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PSMF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:147,238,111...147,263,275
Ensembl chr 3:147,238,114...147,263,275
|
|
G |
Ptbp1 |
polypyrimidine tract binding protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PTBP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:12,663,965...12,673,723
Ensembl chr 7:12,663,965...12,673,718
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of PTGS2 mRNA; Bortezomib results in increased expression of PTGS2 protein NFKBIA protein mutant form inhibits the reaction [Bortezomib results in increased expression of PTGS2 protein] |
CTD |
PMID:21215737 PMID:24085292 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
decreases expression |
ISO |
Bortezomib results in decreased expression of PTHLH mRNA |
CTD |
PMID:18089816 |
|
NCBI chr 4:181,663,425...181,674,181
|
|
G |
Ptp4a3 |
protein tyrosine phosphatase 4A3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PTP4A3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:114,969,699...115,002,902
Ensembl chr 7:114,997,103...115,002,902
|
|
G |
Ptpn11 |
protein tyrosine phosphatase, non-receptor type 11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PTPN11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:40,895,515...40,955,999
Ensembl chr12:40,895,515...40,955,999
|
|
G |
Ptpn6 |
protein tyrosine phosphatase, non-receptor type 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PTPN6 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 4:157,239,141...157,263,890
Ensembl chr 4:157,239,142...157,263,890
|
|
G |
Ptx3 |
pentraxin 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PTX3 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 2:158,097,843...158,103,653
Ensembl chr 2:158,097,843...158,103,653
|
|
G |
R3hdm4 |
R3H domain containing 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of R3HDM4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:12,611,476...12,618,586
Ensembl chr 7:12,611,468...12,618,586
|
|
G |
Rab5a |
RAB5A, member RAS oncogene family |
decreases expression |
ISO |
Bortezomib results in decreased expression of RAB5A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:5,910...6,065
|
|
G |
Rab8b |
RAB8B, member RAS oncogene family |
decreases expression |
ISO |
Bortezomib results in decreased expression of RAB8B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:72,641,680...72,714,646
Ensembl chr 8:72,638,003...72,714,664
|
|
G |
Rac2 |
Rac family small GTPase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of RAC2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:119,769,708...119,797,111
Ensembl chr 7:119,783,849...119,797,098
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of RAD51 mRNA |
CTD |
PMID:21917757 |
|
NCBI chr 3:110,918,240...110,942,920
Ensembl chr 3:110,918,243...110,942,917
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions decreases expression |
ISO |
[Bortezomib co-treated with Butyrates] results in decreased expression of RAF1 protein; [Bortezomib co-treated with panobinostat] results in decreased expression of RAF1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of RAF1 protein Bortezomib results in decreased expression of RAF1 protein |
CTD |
PMID:12893773 PMID:18445700 |
|
NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
|
|
G |
Rala |
RAS like proto-oncogene A |
increases expression |
ISO |
Bortezomib results in increased expression of RALA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:49,676,073...49,729,133
Ensembl chr17:49,714,294...49,727,664
|
|
G |
Rapgef1 |
Rap guanine nucleotide exchange factor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of RAPGEF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:8,189,594...8,307,077
Ensembl chr 3:8,192,575...8,304,976
|
|
G |
Raph1 |
Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 |
increases expression |
ISO |
Bortezomib results in increased expression of RAPH1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:67,290,004...67,370,208
Ensembl chr 9:67,293,309...67,341,341
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions increases response to substance |
ISO |
[Bortezomib co-treated with Butyrates] results in increased degradation of RB1 protein; [Bortezomib co-treated with vorinostat] results in increased degradation of RB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; [RB1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein] |
CTD |
PMID:12893773 PMID:25522274 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rb1cc1 |
RB1-inducible coiled-coil 1 |
increases expression |
ISO |
Bortezomib results in increased expression of RB1CC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:13,033,918...13,097,369
Ensembl chr 5:13,033,918...13,097,341
|
|
G |
Rcan3 |
RCAN family member 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of RCAN3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:153,773,461...153,790,271
Ensembl chr 5:153,773,663...153,790,157
|
|
G |
Rdh11 |
retinol dehydrogenase 11 |
increases expression |
ISO |
Bortezomib results in increased expression of RDH11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:102,356,498...102,372,618
Ensembl chr 6:102,356,492...102,372,611
|
|
G |
Rdh13 |
retinol dehydrogenase 13 |
increases expression |
ISO |
Bortezomib results in increased expression of RDH13 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:72,956,017...72,983,811
Ensembl chr 1:72,956,026...72,984,350
|
|
G |
Recql4 |
RecQ like helicase 4 |
increases expression |
ISO |
Bortezomib results in increased expression of RECQL4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:117,765,892...117,773,128
Ensembl chr 7:117,763,783...117,773,134
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases expression decreases activity |
ISO |
[Bortezomib co-treated with arsenic trioxide] results in decreased activity of RELA protein; [Bortezomib co-treated with trichostatin A] results in decreased expression of and results in decreased activity of RELA protein; [Bortezomib co-treated with trichostatin A] results in decreased expression of RELA protein; [Bortezomib co-treated with vorinostat] results in decreased activity of [NFKB1 protein binds to RELA protein]; [resveratrol co-treated with Bortezomib] results in decreased activity of [RELA protein binds to NFKB1 protein]; Bortezomib inhibits the reaction [belinostat results in increased acetylation of RELA protein]; Bortezomib inhibits the reaction [romidepsin results in increased acetylation of RELA protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of RELA protein]] Bortezomib results in decreased expression of RELA mRNA; Bortezomib results in decreased expression of RELA protein Bortezomib results in decreased activity of RELA protein |
CTD |
PMID:12893773 PMID:16230421 PMID:16904634 PMID:17164350 PMID:17626072 PMID:18223231 PMID:18593997 PMID:20471514 PMID:20977926 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rffl |
ring finger and FYVE-like domain containing E3 ubiquitin protein ligase |
increases expression |
ISO |
Bortezomib results in increased expression of RFFL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:70,157,621...70,220,618
Ensembl chr10:70,157,621...70,220,582
|
|
G |
RGD1359158 |
similar to RIKEN cDNA 1110059E24 |
increases expression |
ISO |
Bortezomib results in increased expression of C9ORF85 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:239,207,869...239,265,997
Ensembl chr 1:239,207,869...239,265,997
|
|
G |
RGD1560436 |
similar to hypothetical protein FLJ20508 |
increases expression |
ISO |
Bortezomib results in increased expression of C1ORF109 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:142,933,619...142,940,807
Ensembl chr 5:142,933,619...142,938,925
|
|
G |
RGD1561113 |
similar to Hypothetical UPF0184 protein C9orf16 homolog |
decreases expression |
ISO |
Bortezomib results in decreased expression of C9ORF16 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:11,408,076...11,410,907
Ensembl chr 3:11,408,348...11,410,732
|
|
G |
Rhobtb2 |
Rho-related BTB domain containing 2 |
increases response to substance |
ISO |
RHOBTB2 gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr15:51,465,148...51,485,562
Ensembl chr15:51,465,148...51,485,692
|
|
G |
Rhot2 |
ras homolog family member T2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of RHOT2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:15,205,943...15,211,739
Ensembl chr10:15,205,534...15,211,325
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
decreases expression increases expression |
ISO |
Bortezomib results in decreased expression of RIPK1 mRNA Bortezomib results in increased expression of RIPK1 protein |
CTD |
PMID:20471514 PMID:26769846 |
|
NCBI chr17:31,537,580...31,569,904
Ensembl chr17:31,537,591...31,569,904
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
increases expression |
ISO |
Bortezomib results in increased expression of RIPK3 protein |
CTD |
PMID:26769846 |
|
NCBI chr15:34,470,796...34,479,741
Ensembl chr15:34,470,796...34,479,741
|
|
G |
Rit1 |
Ras-like without CAAX 1 |
increases expression |
ISO |
Bortezomib results in increased expression of RIT1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:188,087,486...188,099,444
Ensembl chr 2:188,087,486...188,099,444
|
|
G |
Rnd3 |
Rho family GTPase 3 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 3:36,643,374...36,660,727
Ensembl chr 3:36,642,587...36,660,758
|
|
G |
Rnf11 |
ring finger protein 11 |
increases expression |
ISO |
Bortezomib results in increased expression of RNF11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:129,296,271...129,298,513
|
|
G |
Rnf138 |
ring finger protein 138 |
increases expression |
ISO |
Bortezomib results in increased expression of RNF138 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:15,146,925...15,167,361
|
|
G |
Rnf14 |
ring finger protein 14 |
increases expression |
ISO |
Bortezomib results in increased expression of RNF14 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:31,443,424...31,468,641
Ensembl chr18:31,444,472...31,468,640
|
|
G |
Rnf2 |
ring finger protein 2 |
increases expression |
ISO |
Bortezomib results in increased expression of RNF2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:68,829,714...68,859,920
Ensembl chr13:68,830,620...68,858,809
|
|
G |
Rpa3 |
replication protein A3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of RPA3 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 4:34,279,320...34,282,351
Ensembl chr 4:34,279,320...34,282,351
|
|
G |
Rpap3 |
RNA polymerase II associated protein 3 |
increases expression |
ISO |
Bortezomib results in increased expression of RPAP3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:139,167,302...139,196,468
Ensembl chr 7:139,167,303...139,196,416
|
|
G |
Rpl26 |
ribosomal protein L26 |
increases expression |
ISO |
Bortezomib results in increased expres | |